Skip to main content
Psychedex
Sources
21
1 strong · 15 moderate · 5 weak

Studies and references cited across this article, graded by evidence strength.

Claims checked
73
57verified2partial14inconclusive

Inconclusive means the cited source neither confirms nor refutes the claim — a lower-confidence badge, not an error.

Generated
May 8, 2026 · pipeline-v5
Values approved
131/131 (100%)

Data points an editor reviewed and accepted for publication.

01

Value Provenance

Dosing

oraltrace

FieldPublishedAI ProposedConfidence
Threshold15 mg15 mglow
Low20–50 mg20–50 mglow
Common50–100 mg50–100 mglow
Strong100–135 mg100–135 mglow
Heavy135+ mg135+ mglow
Editorial

User-report data from KnowDrugs platform only. Light (20–50 mg), common (50–100 mg), strong (100–135 mg) directly from community reports. Threshold (~15 mg) inferred from low end of light range. Heavy (>135 mg) inferred as upper boundary. No controlled dosing study exists for 2-MMC. All values are safety-critical and unverified.

Reasoning

User-report data from KnowDrugs platform only. Light (20–50 mg), common (50–100 mg), strong (100–135 mg) directly from community reports. Threshold (~15 mg) inferred from low end of light range. Heavy (>135 mg) inferred as upper boundary. No controlled dosing study exists for 2-MMC. All values are safety-critical and unverified.

Evidence basis: community_consensus_small

insufflatedtrace

FieldPublishedAI ProposedConfidence
Threshold3 mg3 mglow
Low5–15 mg5–15 mglow
Common15–40 mg15–40 mglow
Strong40–80 mg40–80 mglow
Heavy80+ mg80+ mglow
Editorial

User-report data from KnowDrugs platform only. Light (5–15 mg), common (15–40 mg), strong (40–80 mg) directly from community reports. Threshold (~3 mg) inferred from low end of light range. Heavy (>80 mg) inferred as upper boundary. Insufflated doses substantially lower than oral, consistent with higher nasal bioavailability for cathinones. No controlled dosing study exists.

Reasoning

User-report data from KnowDrugs platform only. Light (5–15 mg), common (15–40 mg), strong (40–80 mg) directly from community reports. Threshold (~3 mg) inferred from low end of light range. Heavy (>80 mg) inferred as upper boundary. Insufflated doses substantially lower than oral, consistent with higher nasal bioavailability for cathinones. No controlled dosing study exists.

Evidence basis: community_consensus_small

Duration

oral

FieldPublishedAI ProposedConfidence
Onsettrace15–30 minutes15–30 minuteslow
Editorial

Structural-analog estimate from 3-MMC and 4-MMC oral onset times. No 2-MMC-specific onset data published.

Reasoning

Structural-analog estimate from 3-MMC and 4-MMC oral onset times. No 2-MMC-specific onset data published.

Evidence basis: structural_analogy

Come uptrace15–30 minutes15–30 minuteslow
Editorial

Structural-analog estimate from 3-MMC/4-MMC. No 2-MMC-specific data.

Reasoning

Structural-analog estimate from 3-MMC/4-MMC. No 2-MMC-specific data.

Evidence basis: structural_analogy

Peaktrace30–60 minutes30–60 minuteslow
Editorial

Structural-analog estimate from 3-MMC/4-MMC. Consistent with van Amsterdam 2025 noting shorter duration than mephedrone.

Reasoning

Structural-analog estimate from 3-MMC/4-MMC. Consistent with van Amsterdam 2025 noting shorter duration than mephedrone.

Evidence basis: structural_analogy

Offsettrace30–60 minutes30–60 minuteslow
Editorial

Structural-analog estimate from 3-MMC/4-MMC cathinone class offset patterns.

Reasoning

Structural-analog estimate from 3-MMC/4-MMC cathinone class offset patterns.

Evidence basis: structural_analogy

Totaltrace2–4 hours2–4 hourslow
Editorial

User-report supported total duration, consistent with van Amsterdam 2025 noting 'shorter than 4-MMC'. This is the only duration value with any direct evidence for 2-MMC.

Reasoning

User-report supported total duration, consistent with van Amsterdam 2025 noting 'shorter than 4-MMC'. This is the only duration value with any direct evidence for 2-MMC.

Evidence basis: community_consensus_small

After effectstrace2–6 hours2–6 hourslow
Editorial

Class estimate from stimulant cathinone aftereffect patterns. Includes residual wakefulness, fatigue, and dysphoria.

Reasoning

Class estimate from stimulant cathinone aftereffect patterns. Includes residual wakefulness, fatigue, and dysphoria.

Evidence basis: structural_analogy

insufflated

FieldPublishedAI ProposedConfidence
Onsettrace2–5 minutes2–5 minuteslow
Editorial

Structural-analog estimate from insufflated 3-MMC/4-MMC. Rapid nasal absorption consistent with cathinone class.

Reasoning

Structural-analog estimate from insufflated 3-MMC/4-MMC. Rapid nasal absorption consistent with cathinone class.

Evidence basis: structural_analogy

Come uptrace5–15 minutes5–15 minuteslow
Editorial

Structural-analog estimate from insufflated cathinone class patterns.

Reasoning

Structural-analog estimate from insufflated cathinone class patterns.

Evidence basis: structural_analogy

Peaktrace15–45 minutes15–45 minuteslow
Editorial

Structural-analog estimate. Insufflated peak shorter and sharper than oral, consistent with cathinone class pharmacokinetics.

Reasoning

Structural-analog estimate. Insufflated peak shorter and sharper than oral, consistent with cathinone class pharmacokinetics.

Evidence basis: structural_analogy

Offsettrace15–30 minutes15–30 minuteslow
Editorial

Structural-analog estimate from insufflated cathinone class offset patterns.

Reasoning

Structural-analog estimate from insufflated cathinone class offset patterns.

Evidence basis: structural_analogy

Totaltrace1–3 hours1–3 hourslow
Editorial

Structural-analog estimate; shorter than oral per class pattern for insufflated cathinones. No direct 2-MMC insufflated duration data.

Reasoning

Structural-analog estimate; shorter than oral per class pattern for insufflated cathinones. No direct 2-MMC insufflated duration data.

Evidence basis: structural_analogy

After effectstrace2–6 hours2–6 hourslow
Editorial

Class estimate from stimulant cathinone aftereffect patterns. Includes nasal discomfort, fatigue, and dysphoria.

Reasoning

Class estimate from stimulant cathinone aftereffect patterns. Includes nasal discomfort, fatigue, and dysphoria.

Evidence basis: structural_analogy

Safety

Toxicity Profiletrace

FieldPublishedAI ProposedConfidence
Acutemoderatemoderatelow
Chronicmoderatemoderatelow
Organs Affectedcardiovascular, hepatic, neurologicalcardiovascular, hepatic, neurologicallow
Editorial

All toxicity data are class-extrapolated from 3-MMC and 4-MMC. Evidence discount applied: raw findings from class data (moderate-to-high cardiovascular/hepatic/neurological risk) are proposed at 'moderate' given no 2-MMC-specific confirmation. Reference compounds: 3-MMC (hepatotoxicity, STRIDA toxidrome frequencies), 4-MMC/mephedrone (cardiovascular case series, neurotoxicity with alcohol potentiation).

Reasoning

All toxicity data are class-extrapolated from 3-MMC and 4-MMC. Evidence discount applied: raw findings from class data (moderate-to-high cardiovascular/hepatic/neurological risk) are proposed at 'moderate' given no 2-MMC-specific confirmation. Reference compounds: 3-MMC (hepatotoxicity, STRIDA toxidrome frequencies), 4-MMC/mephedrone (cardiovascular case series, neurotoxicity with alcohol potentiation).

Evidence basis: structural_analogy

Dependence Profiletrace

FieldPublishedAI ProposedConfidence
Physicalnegligiblenegligiblelow
Psychologicalhighhighlow
Compulsive Redosinghighhighlow
Dose Escalationmoderatemoderatelow
Editorial

No 2-MMC-specific dependence data. Classification based on: van Amsterdam 2025 noting greater craving/redosing than mephedrone for 2/3-MMC; Liechti 2015 framework positioning high DAT/SERT ratio compounds as high addiction potential; 3-MMC treatment-seeking trends. Reference compounds: 3-MMC, 4-MMC (mephedrone).

Reasoning

No 2-MMC-specific dependence data. Classification based on: van Amsterdam 2025 noting greater craving/redosing than mephedrone for 2/3-MMC; Liechti 2015 framework positioning high DAT/SERT ratio compounds as high addiction potential; 3-MMC treatment-seeking trends. Reference compounds: 3-MMC, 4-MMC (mephedrone).

Evidence basis: structural_analogy

Withdrawal Profiletrace

FieldPublishedAI ProposedConfidence
Severitymoderatemoderatelow
Symptomsfatigue, hypersomnia, increased appetite, dysphoria, anhedonia, craving, psychomotor retardation, irritabilityfatigue, hypersomnia, increased appetite, dysphoria, anhedonia, craving, psychomotor retardation, irritabilitylow
FatalNoNolow
Medical SupervisionNot requiredNot requiredlow
Editorial

No published withdrawal characterization for 2-MMC. Withdrawal profile inferred from amphetamine-type stimulant class. Physical withdrawal not life-threatening; psychological symptoms (craving, anhedonia) may be prolonged. Reference: cathinone class review (Debruyne 2014).

Reasoning

No published withdrawal characterization for 2-MMC. Withdrawal profile inferred from amphetamine-type stimulant class. Physical withdrawal not life-threatening; psychological symptoms (craving, anhedonia) may be prolonged. Reference: cathinone class review (Debruyne 2014).

Evidence basis: structural_analogy

Tolerance Profiletrace

FieldPublishedAI ProposedConfidence
Buildupmoderatemoderatelow
Half-life3 days3 dayslow
Full Reset10 days10 dayslow
Cross-tolerancesamphetamine, methamphetamine, MDMA, 3-MMC, mephedrone, cocaineamphetamine, methamphetamine, MDMA, 3-MMC, mephedrone, cocainelow
Editorial

Class inference from stimulant cathinone pharmacology. Tolerance mechanism (D2 downregulation, reduced DA synthesis) well-established for amphetamine-type stimulants. Cross-tolerances expected from shared DAT/NET/SERT mechanism. Reference compounds: amphetamine, 3-MMC, mephedrone.

Reasoning

Class inference from stimulant cathinone pharmacology. Tolerance mechanism (D2 downregulation, reduced DA synthesis) well-established for amphetamine-type stimulants. Cross-tolerances expected from shared DAT/NET/SERT mechanism. Reference compounds: amphetamine, 3-MMC, mephedrone.

Evidence basis: structural_analogy

Effects & Profile

Contraindications

FieldPublishedAI ProposedConfidence
cardiovascular Cardiovascular diseasetraceabsoluteabsolutelow
Editorial

Class-extrapolated from 3-MMC/4-MMC case series (Groenewegen 2024). Tachycardia in 48% of cathinone intoxication presentations. No 2-MMC-specific cardiac events published.

Reasoning

Class-extrapolated from 3-MMC/4-MMC case series (Groenewegen 2024). Tachycardia in 48% of cathinone intoxication presentations. No 2-MMC-specific cardiac events published.

other Concurrent MAOI therapytraceabsoluteabsolutemedium
Editorial

Mechanism-based absolute contraindication for all monoamine releasing agents. No 2-MMC-specific data needed; pharmacological mechanism is sufficient.

Reasoning

Mechanism-based absolute contraindication for all monoamine releasing agents. No 2-MMC-specific data needed; pharmacological mechanism is sufficient.

neurological Seizure disorderstracerelativerelativelow
Editorial

Class-extrapolated from 3-MMC STRIDA data showing 8% seizure incidence in intoxication presentations. Mechanism shared across cathinone class.

Reasoning

Class-extrapolated from 3-MMC STRIDA data showing 8% seizure incidence in intoxication presentations. Mechanism shared across cathinone class.

hepatic Hepatic impairmenttracerelativerelativelow
Editorial

Inferred from 3-MMC rat hepatocyte cytotoxicity study (Dias da Silva 2019) showing CYP2D6/CYP2E1 involvement in toxic metabolite generation. No 2-MMC-specific hepatotoxicity data.

Reasoning

Inferred from 3-MMC rat hepatocyte cytotoxicity study (Dias da Silva 2019) showing CYP2D6/CYP2E1 involvement in toxic metabolite generation. No 2-MMC-specific hepatotoxicity data.

psychiatric Active psychosis, bipolar disorder, severe anxietytracerelativerelativelow
Editorial

Class-extrapolated from cathinone systematic review (Daziani 2023) and STRIDA intoxication data. Dopaminergic mechanism predicts psychiatric exacerbation in vulnerable populations.

Reasoning

Class-extrapolated from cathinone systematic review (Daziani 2023) and STRIDA intoxication data. Dopaminergic mechanism predicts psychiatric exacerbation in vulnerable populations.

pregnancy breastfeeding Pregnancy and lactationtraceabsoluteabsolutelow
Editorial

Class mechanism-based contraindication for sympathomimetic stimulants. No 2-MMC-specific reproductive data exist.

Reasoning

Class mechanism-based contraindication for sympathomimetic stimulants. No 2-MMC-specific reproductive data exist.

other Vigorous activity in hot environmentstracerelativerelativelow
Editorial

Class-extrapolated from 3-MMC STRIDA data showing 6% hyperthermia incidence. Environmental factors compound pharmacological thermogenic risk.

Reasoning

Class-extrapolated from 3-MMC STRIDA data showing 6% hyperthermia incidence. Environmental factors compound pharmacological thermogenic risk.

Timeline Phases

oral

FieldPublishedAI ProposedConfidence
Onsettrace900–1800 sec(i=0.15)900–1800 sec(i=0.15)low
Editorial

All phase durations are structural-analog estimates from 3-MMC and 4-MMC oral pharmacokinetics. Total oral duration (2–4 hours) supported by user reports and van Amsterdam 2025 noting shorter duration than mephedrone. Phase intensity weights from work-notes. No controlled PK data for 2-MMC exist. Reference compounds: 3-MMC, 4-MMC (mephedrone).

Reasoning

All phase durations are structural-analog estimates from 3-MMC and 4-MMC oral pharmacokinetics. Total oral duration (2–4 hours) supported by user reports and van Amsterdam 2025 noting shorter duration than mephedrone. Phase intensity weights from work-notes. No controlled PK data for 2-MMC exist. Reference compounds: 3-MMC, 4-MMC (mephedrone).

Evidence basis: structural_analogy

Come uptrace900–1800 sec(i=0.45)900–1800 sec(i=0.45)low
Editorial

All phase durations are structural-analog estimates from 3-MMC and 4-MMC oral pharmacokinetics. Total oral duration (2–4 hours) supported by user reports and van Amsterdam 2025 noting shorter duration than mephedrone. Phase intensity weights from work-notes. No controlled PK data for 2-MMC exist. Reference compounds: 3-MMC, 4-MMC (mephedrone).

Reasoning

All phase durations are structural-analog estimates from 3-MMC and 4-MMC oral pharmacokinetics. Total oral duration (2–4 hours) supported by user reports and van Amsterdam 2025 noting shorter duration than mephedrone. Phase intensity weights from work-notes. No controlled PK data for 2-MMC exist. Reference compounds: 3-MMC, 4-MMC (mephedrone).

Evidence basis: structural_analogy

Peaktrace1800–3600 sec(i=1.00)1800–3600 sec(i=1.00)low
Editorial

All phase durations are structural-analog estimates from 3-MMC and 4-MMC oral pharmacokinetics. Total oral duration (2–4 hours) supported by user reports and van Amsterdam 2025 noting shorter duration than mephedrone. Phase intensity weights from work-notes. No controlled PK data for 2-MMC exist. Reference compounds: 3-MMC, 4-MMC (mephedrone).

Reasoning

All phase durations are structural-analog estimates from 3-MMC and 4-MMC oral pharmacokinetics. Total oral duration (2–4 hours) supported by user reports and van Amsterdam 2025 noting shorter duration than mephedrone. Phase intensity weights from work-notes. No controlled PK data for 2-MMC exist. Reference compounds: 3-MMC, 4-MMC (mephedrone).

Evidence basis: structural_analogy

Plateautrace900–1800 sec(i=0.50)900–1800 sec(i=0.50)low
Editorial

All phase durations are structural-analog estimates from 3-MMC and 4-MMC oral pharmacokinetics. Total oral duration (2–4 hours) supported by user reports and van Amsterdam 2025 noting shorter duration than mephedrone. Phase intensity weights from work-notes. No controlled PK data for 2-MMC exist. Reference compounds: 3-MMC, 4-MMC (mephedrone).

Reasoning

All phase durations are structural-analog estimates from 3-MMC and 4-MMC oral pharmacokinetics. Total oral duration (2–4 hours) supported by user reports and van Amsterdam 2025 noting shorter duration than mephedrone. Phase intensity weights from work-notes. No controlled PK data for 2-MMC exist. Reference compounds: 3-MMC, 4-MMC (mephedrone).

Evidence basis: structural_analogy

Resolutiontrace1800–3600 sec(i=0.20)1800–3600 sec(i=0.20)low
Editorial

All phase durations are structural-analog estimates from 3-MMC and 4-MMC oral pharmacokinetics. Total oral duration (2–4 hours) supported by user reports and van Amsterdam 2025 noting shorter duration than mephedrone. Phase intensity weights from work-notes. No controlled PK data for 2-MMC exist. Reference compounds: 3-MMC, 4-MMC (mephedrone).

Reasoning

All phase durations are structural-analog estimates from 3-MMC and 4-MMC oral pharmacokinetics. Total oral duration (2–4 hours) supported by user reports and van Amsterdam 2025 noting shorter duration than mephedrone. Phase intensity weights from work-notes. No controlled PK data for 2-MMC exist. Reference compounds: 3-MMC, 4-MMC (mephedrone).

Evidence basis: structural_analogy

Afterglowtrace7200–21600 sec(i=0.15)7200–21600 sec(i=0.15)low
Editorial

All phase durations are structural-analog estimates from 3-MMC and 4-MMC oral pharmacokinetics. Total oral duration (2–4 hours) supported by user reports and van Amsterdam 2025 noting shorter duration than mephedrone. Phase intensity weights from work-notes. No controlled PK data for 2-MMC exist. Reference compounds: 3-MMC, 4-MMC (mephedrone).

Reasoning

All phase durations are structural-analog estimates from 3-MMC and 4-MMC oral pharmacokinetics. Total oral duration (2–4 hours) supported by user reports and van Amsterdam 2025 noting shorter duration than mephedrone. Phase intensity weights from work-notes. No controlled PK data for 2-MMC exist. Reference compounds: 3-MMC, 4-MMC (mephedrone).

Evidence basis: structural_analogy

insufflated

FieldPublishedAI ProposedConfidence
Onsettrace120–300 sec(i=0.30)120–300 sec(i=0.30)low
Editorial

All phase durations are structural-analog estimates from insufflated 3-MMC and 4-MMC. Insufflated route produces faster onset, sharper peak, and shorter total duration than oral, consistent with cathinone class pharmacokinetics. No controlled PK data for insufflated 2-MMC exist. Phase intensity weights from work-notes. Reference compounds: 3-MMC, 4-MMC (mephedrone).

Reasoning

All phase durations are structural-analog estimates from insufflated 3-MMC and 4-MMC. Insufflated route produces faster onset, sharper peak, and shorter total duration than oral, consistent with cathinone class pharmacokinetics. No controlled PK data for insufflated 2-MMC exist. Phase intensity weights from work-notes. Reference compounds: 3-MMC, 4-MMC (mephedrone).

Evidence basis: structural_analogy

Come uptrace300–600 sec(i=0.60)300–600 sec(i=0.60)low
Editorial

All phase durations are structural-analog estimates from insufflated 3-MMC and 4-MMC. Insufflated route produces faster onset, sharper peak, and shorter total duration than oral, consistent with cathinone class pharmacokinetics. No controlled PK data for insufflated 2-MMC exist. Phase intensity weights from work-notes. Reference compounds: 3-MMC, 4-MMC (mephedrone).

Reasoning

All phase durations are structural-analog estimates from insufflated 3-MMC and 4-MMC. Insufflated route produces faster onset, sharper peak, and shorter total duration than oral, consistent with cathinone class pharmacokinetics. No controlled PK data for insufflated 2-MMC exist. Phase intensity weights from work-notes. Reference compounds: 3-MMC, 4-MMC (mephedrone).

Evidence basis: structural_analogy

Peaktrace900–2700 sec(i=1.00)900–2700 sec(i=1.00)low
Editorial

All phase durations are structural-analog estimates from insufflated 3-MMC and 4-MMC. Insufflated route produces faster onset, sharper peak, and shorter total duration than oral, consistent with cathinone class pharmacokinetics. No controlled PK data for insufflated 2-MMC exist. Phase intensity weights from work-notes. Reference compounds: 3-MMC, 4-MMC (mephedrone).

Reasoning

All phase durations are structural-analog estimates from insufflated 3-MMC and 4-MMC. Insufflated route produces faster onset, sharper peak, and shorter total duration than oral, consistent with cathinone class pharmacokinetics. No controlled PK data for insufflated 2-MMC exist. Phase intensity weights from work-notes. Reference compounds: 3-MMC, 4-MMC (mephedrone).

Evidence basis: structural_analogy

Plateautrace600–1800 sec(i=0.40)600–1800 sec(i=0.40)low
Editorial

All phase durations are structural-analog estimates from insufflated 3-MMC and 4-MMC. Insufflated route produces faster onset, sharper peak, and shorter total duration than oral, consistent with cathinone class pharmacokinetics. No controlled PK data for insufflated 2-MMC exist. Phase intensity weights from work-notes. Reference compounds: 3-MMC, 4-MMC (mephedrone).

Reasoning

All phase durations are structural-analog estimates from insufflated 3-MMC and 4-MMC. Insufflated route produces faster onset, sharper peak, and shorter total duration than oral, consistent with cathinone class pharmacokinetics. No controlled PK data for insufflated 2-MMC exist. Phase intensity weights from work-notes. Reference compounds: 3-MMC, 4-MMC (mephedrone).

Evidence basis: structural_analogy

Resolutiontrace900–1800 sec(i=0.20)900–1800 sec(i=0.20)low
Editorial

All phase durations are structural-analog estimates from insufflated 3-MMC and 4-MMC. Insufflated route produces faster onset, sharper peak, and shorter total duration than oral, consistent with cathinone class pharmacokinetics. No controlled PK data for insufflated 2-MMC exist. Phase intensity weights from work-notes. Reference compounds: 3-MMC, 4-MMC (mephedrone).

Reasoning

All phase durations are structural-analog estimates from insufflated 3-MMC and 4-MMC. Insufflated route produces faster onset, sharper peak, and shorter total duration than oral, consistent with cathinone class pharmacokinetics. No controlled PK data for insufflated 2-MMC exist. Phase intensity weights from work-notes. Reference compounds: 3-MMC, 4-MMC (mephedrone).

Evidence basis: structural_analogy

Afterglowtrace3600–21600 sec(i=0.15)3600–21600 sec(i=0.15)low
Editorial

All phase durations are structural-analog estimates from insufflated 3-MMC and 4-MMC. Insufflated route produces faster onset, sharper peak, and shorter total duration than oral, consistent with cathinone class pharmacokinetics. No controlled PK data for insufflated 2-MMC exist. Phase intensity weights from work-notes. Reference compounds: 3-MMC, 4-MMC (mephedrone).

Reasoning

All phase durations are structural-analog estimates from insufflated 3-MMC and 4-MMC. Insufflated route produces faster onset, sharper peak, and shorter total duration than oral, consistent with cathinone class pharmacokinetics. No controlled PK data for insufflated 2-MMC exist. Phase intensity weights from work-notes. Reference compounds: 3-MMC, 4-MMC (mephedrone).

Evidence basis: structural_analogy

Dose Tier Summaries

lighttrace
low

Noticeable stimulation and mood elevation emerge at this range. Wakefulness increases, mild euphoria develops, and sociability enhancement becomes apparent — conversations feel easier and more engaging. Thought acceleration begins, with a subtle increase in verbal fluency. Physical effects remain mild: slight heart rate elevation, possible dry mouth, and the early onset of appetite suppression. Pupil dilation may be faintly visible. Bruxism is uncommon at this level. The overall experience is functional and manageable. Insomnia is possible if taken in the evening. The compulsive redosing urge is present but typically manageable at this dose level.

Editorial

Based on KnowDrugs user-report oral light range (20–50 mg) and cathinone-class effect progression. Sociability and mood effects consistent with van Amsterdam 2025 characterization of 2/3-MMC as dopamine-dominant stimulants.

Reasoning

Based on KnowDrugs user-report oral light range (20–50 mg) and cathinone-class effect progression. Sociability and mood effects consistent with van Amsterdam 2025 characterization of 2/3-MMC as dopamine-dominant stimulants.

Evidence basis: community_consensus_small

thresholdtrace
low

Barely perceptible stimulation — a mild increase in alertness and slight elevation in mood that may be difficult to distinguish from placebo or natural variation. Peripheral stimulant effects are minimal: a marginal heart rate increase and faint restlessness may be noticed by attentive users. Physical effects are sub-functional. Appetite suppression is absent or negligible. No meaningful pupil dilation or sympathomimetic signs. This range is primarily useful for assessing individual sensitivity to 2-MMC before committing to a higher dose. Duration of effects at threshold is shorter than at common doses. Sleep is unlikely to be significantly affected if taken early in the day.

Editorial

No controlled threshold data for 2-MMC. Threshold (~15 mg oral) inferred from the low end of KnowDrugs user-report light range and cathinone-class pharmacology. All claims are structural-analog estimates from 3-MMC/4-MMC.

Reasoning

No controlled threshold data for 2-MMC. Threshold (~15 mg oral) inferred from the low end of KnowDrugs user-report light range and cathinone-class pharmacology. All claims are structural-analog estimates from 3-MMC/4-MMC.

Evidence basis: structural_analogy

commontrace
low

Full stimulant profile emerges — clear euphoria, marked energy increase, and pronounced sociability enhancement with increased talkativeness. Cognitive euphoria and thought acceleration are evident. Focus enhancement may be present, along with motivation enhancement. Music enhancement is reported by some users. Sympathomimetic effects become apparent: tachycardia, elevated blood pressure, pupil dilation, and appetite suppression are prominent. Bruxism may emerge. Excessive sweating and temperature dysregulation begin at this level. Dry mouth is common. The compulsive redosing urge becomes noticeable — the short duration of 2-MMC drives a pattern of repeated dosing that is the defining behavioral feature of use at this range. Insomnia is likely for several hours post-dose.

Editorial

Based on KnowDrugs user-report oral common range (50–100 mg). Effect profile from user reports and class extrapolation. Redosing compulsion specifically noted by van Amsterdam 2025 as greater than mephedrone.

Reasoning

Based on KnowDrugs user-report oral common range (50–100 mg). Effect profile from user reports and class extrapolation. Redosing compulsion specifically noted by van Amsterdam 2025 as greater than mephedrone.

Evidence basis: community_consensus_small

strongtrace
low

Intense stimulation with pronounced euphoria dominates the experience. Sociability enhancement is strong, but may tip toward pressured speech and restlessness. Thought acceleration can become disorganized at the upper end of this range. Anxiety and irritability may emerge, particularly during the offset. Sympathomimetic effects are significant — tachycardia, hypertension, excessive sweating, bruxism, and jaw tension are expected. Vasoconstriction may produce cold extremities. Pupil dilation is marked. Temperature dysregulation carries risk in hot environments or during physical exertion. Compulsive redosing urge is strong at this level. Sleep is impossible for several hours post-dose. The comedown period brings pronounced dysphoria, irritability, and fatigue. Risk of paranoia increases with extended sessions.

Editorial

Based on KnowDrugs user-report oral strong range (100–135 mg) and cathinone-class dose-response escalation. Paranoia and anxiety at higher doses documented in user reports and consistent with dopaminergic overstimulation framework (Daziani 2023).

Reasoning

Based on KnowDrugs user-report oral strong range (100–135 mg) and cathinone-class dose-response escalation. Paranoia and anxiety at higher doses documented in user reports and consistent with dopaminergic overstimulation framework (Daziani 2023).

Evidence basis: community_consensus_small

heavytrace
low

Overwhelming stimulation with high cardiovascular risk — severe tachycardia and hypertension are expected. The sympathomimetic toxidrome may fully manifest: agitation, diaphoresis, hyperthermia, and mydriasis. Risk of abnormal heartbeat including potentially dangerous arrhythmias increases substantially. Psychotic-spectrum symptoms become possible at this range — paranoia, hallucinations (visual and auditory), and aggressive behavior are reported for the cathinone class at high doses. Severe bruxism and muscle tension. Confusion and decision impairment compromise safety awareness. Extreme compulsive redosing compulsion. This range approaches acute toxicity thresholds for the cathinone class. Seizure risk is elevated. Hyperthermia risk is significant, especially combined with physical activity. Emergency medical presentation may be required.

Editorial

Heavy range (>135 mg oral) extrapolated from KnowDrugs upper limit and cathinone-class toxidrome data. Psychotic symptoms, seizures, and cardiac events documented in cathinone class case series (Groenewegen 2024, Daziani 2023). No 2-MMC-specific heavy-dose data.

Reasoning

Heavy range (>135 mg oral) extrapolated from KnowDrugs upper limit and cathinone-class toxidrome data. Psychotic symptoms, seizures, and cardiac events documented in cathinone class case series (Groenewegen 2024, Daziani 2023). No 2-MMC-specific heavy-dose data.

Evidence basis: structural_analogy

02

History

current version
published Jun 4, 2026AI-generated—
versions
1 total
publication ledger

backfill Jun 4, 2026

Historical versions do not record which reviewer approved them; editorial accountability is recorded per value in the database and in the publication ledger going forward.

full version history suggest a correctioncontact@psychedex.org
03

Sources

1 strong · 15 moderate · 5 weak
  1. [1]
    moderate
    Appearance of 2-MMC and 3-MMC on the illicit drug market in the Netherlands: A systematic narrative review of the prevalence and risks
    van Amsterdam J, Nabben T, van den Brink W · 2025 · The International journal on drug policy
    doi.org/10.1016/j.drugpo.2025.104971pubmed 4087606814 claims checked12 verified1 partial1 inconclusive
  2. [2]
    weak
    EUDA Initial Report on 2-Methylmethcathinone (2-MMC)
    European Union Drugs Agency (EUDA) · 2025
    linkno claims checked
  3. [3]
    moderate
    Pharmacological characterization of designer cathinones in vitro
    Simmler LD, Buser TA, Donzelli M, et al. · 2012 · British Journal of Pharmacology
    doi.org/10.1111/j.1476-5381.2012.02145.x6 claims checked4 verified2 inconclusive
  4. [4]
    moderate
    Novel psychoactive substances (designer drugs): overview and pharmacology of modulators of monoamine signaling
    Liechti ME · 2015 · Swiss Medical Weekly
    doi.org/10.4414/smw.2015.14043pubmed 255880186 claims checked5 verified1 inconclusive
  5. [5]
    weak
    KnowDrugs: 2-MMC
    KnowDrugs · 2024
    linkno claims checked
  6. [6]
    weak
    Cardiotoxicity After Synthetic Cathinone Use; Two Cases, A Case Series and Scoping Review
    Groenewegen KL, Gresnigt FMJ, Lonkhuyzen JJN, den Haan C, Franssen EJF, Riezebos RK, Ohana D, de Lange DW · 2024 · Cardiovascular toxicology
    doi.org/10.1007/s12012-024-09832-xpubmed 384118514 claims checked3 verified1 partial
  7. [7]
    moderate
    Separation of ortho, meta and para isomers of methylmethcathinone (MMC) and methylethcathinone (MEC) using LC-ESI-MS/MS: Application to forensic serum samples
    Maas A, Sydow K, Madea B, Hess C · 2017 · Journal of chromatography. B, Analytical technologies in the biomedical and life sciences
    doi.org/10.1016/j.jchromb.2017.01.046pubmed 282624464 claims checked4 verified
  8. [8]
    weak
    EU takes action to control three harmful new drugs
    European Union Drugs Agency (EUDA) · 2026
    linkno claims checked
  9. [9]
    moderate
    A review of synthetic cathinones emerging in recent years (2019–2022).
    Kuropka P, Zawadzki M, Szpot P · 2022 · Forensic Toxicology
    doi.org/10.1007/s11419-022-00639-5pubmed 361241071 claim checked1 verified
  10. [10]
    moderate
    The prevalence of new psychoactive substances in biological material - a three-year review of casework in Poland.
    Adamowicz P, Gieroń J, Gil D, Lechowicz W, Skulska A, Tokarczyk B · 2016 · Drug Testing and Analysis
    doi.org/10.1002/dta.1924pubmed 266666291 claim checked1 verified
  11. [11]
    moderate
    Simultaneous enantioselective determination of 2-, 3-, and 4-methylmethcathinones; their isomers; and major phase-1 metabolites in oral fluid of drug abusers using enantioselective high-performance liquid chromatography-tandem mass spectrometry
    Kobidze G, Faro AFL, Balloni A, Sprega G, Massano M, Wille SMR, Basile G, Farkas T, Tini A, Busardò FP, Chankvetadze B · 2025 · Analytical and bioanalytical chemistry
    doi.org/10.1007/s00216-025-05838-8pubmed 401336476 claims checked6 verified
  12. [12]
    moderate
    Stereoselective Differences between the Reinforcing and Motivational Effects of Cathinone-Derived 4-Methylmethcathinone (Mephedrone) in Self-Administering Rats
    Philogene-Khalid HL, Simmons SJ, Nayak S, et al. · 2017 · ACS Chemical Neuroscience
    doi.org/10.1021/acschemneuro.7b00212pubmed 288850071 claim checked1 verified
  13. [13]
    moderate
    Thermodynamics of acid-base dissociation of several cathinones and 1-phenylethylamine, studied by an accurate capillary electrophoresis method free from the Joule heating impact
    Nowak PM, Woźniakiewicz M, Mitoraj M, Sagan F, Kościelniak P · 2018 · Journal of chromatography. A
    doi.org/10.1016/j.chroma.2018.01.047pubmed 294095962 claims checked2 verified
  14. [14]
    moderate
    The designer methcathinone analogs, mephedrone and methylone, are substrates for monoamine transporters in brain tissue
    Baumann MH, Ayestas MA, Partilla JS, et al. · 2012 · Neuropsychopharmacology
    doi.org/10.1038/npp.2011.304pubmed 221699432 claims checked2 verified
  15. [15]
    moderate
    The new psychoactive substance 3-methylmethcathinone (3-MMC or metaphedrone) induces oxidative stress, apoptosis, and autophagy in primary rat hepatocytes at human-relevant concentrations
    Dias da Silva D, Ferreira B, Roque Bravo R, Rebelo R, Duarte de Almeida T, Valente MJ, Silva JP, Carvalho F, Bastos ML, Carmo H · 2019 · Archives of toxicology
    doi.org/10.1007/s00204-019-02539-xpubmed 314681015 claims checked5 verified
  16. [16]
    moderate
    The combination of ethanol with mephedrone increases the signs of neurotoxicity and impairs neurogenesis and learning in adolescent CD-1 mice.
    Ciudad-Roberts A, Duart-Castells L, Camarasa J, Pubill D, Escubedo E · 2016 · Toxicology and applied pharmacology
    doi.org/10.1016/j.taap.2015.12.019pubmed 267473014 claims checked4 verified
  17. [17]
    moderate
    Underreporting of synthetic cathinone poisoning with clinical immunoassays: An experimental and observational study.
    Willeman T, Laudet M, Revol B, Boudin C, Eysseric-Guerin H, Scolan V, Stanke-Labesque F · 2025 · Annals of clinical biochemistry
    doi.org/10.1177/00045632251331404pubmed 401188112 claims checked2 verified
  18. [18]
    moderate
    Emerging drugs of abuse: current perspectives on substituted cathinones
    Debruyne D, Loilier M, Cesbron A, Le Boisselier R, Bourgine J · 2014 · Substance Abuse and Rehabilitation
    doi.org/10.2147/sar.s37257pubmed 249667136 claims checked1 verified5 inconclusive
  19. [19]
    strong
    Synthetic Cathinones and Neurotoxicity Risks: A Systematic Review
    Daziani G, Lo Faro AF, Montana V, Goteri G, Pesaresi M, Bambagiotti G, Montanari E, Giorgetti R, Montana A · 2023 · International Journal of Molecular Sciences
    doi.org/10.3390/ijms24076230pubmed 370472014 claims checked4 verified
  20. [20]
    moderate
    Metaphedrone (3-Methylmethcathinone): Pharmacological, Clinical, and Toxicological Profile
    Kelecević I, Vejnović AM, Javorac J, Gvozdenović N, Janjić N, Mijatović Jovin V · 2024 · Medicina (Kaunas, Lithuania)
    doi.org/10.3390/medicina60030466pubmed 385411921 claim checked1 inconclusive
  21. [21]
    weak
    Characteristics of analytically confirmed 3-MMC-related intoxications from the Swedish STRIDA project
    Bäckberg M, Lindeman E, Beck O, Helander A · 2015 · Clinical toxicology (Philadelphia, Pa.)
    doi.org/10.3109/15563650.2014.981823pubmed 254228624 claims checked4 inconclusive
04

Claim Verification

Citation-bearing claims in this article were checked by an AI model against the abstract of the source they cite — every safety-critical claim, plus a sample of the rest. Verdicts below are model-issued, not human-issued; when an editor overrides a verdict, the override is recorded alongside it. Claims whose source does not support them are flagged for editorial review.

summary6 claims5verified1partial
partialUser reports indicate a shorter duration of action than mephedrone, with total oral effects estimated at 2–4 hours[1]model confidence 85%
Partial

Abstract confirms shorter duration vs mephedrone (4-MMC) and more craving/redosing, but contains no specific '2–4 hours' figure. The duration estimate is a specific numerical claim not verifiable from this abstract.

Shorter duration leads to more craving and redosing vs 4-MMC.

checked by claude-sonnet-4-6 · May 8, 2026

verifiedNo substance-specific binding affinity data exist. 2-MMC is presumed to act as a non-selective monoamine releasing agent — causing efflux of dopamine, norepinephrine, and serotonin via reverse transport at DAT, NET, and SERT — based on structural analogy to mephedrone and the broader cathinone pharmacological framework[3]model confidence 90%
Verified

Abstract confirms cathinone class pharmacological framework (DAT, NET, SERT efflux classification) and explicitly notes 2-MMC was not individually tested, making structural analogy the only available basis for inference.

Determined potencies at DAT, NET, SERT for uptake inhibition and monoamine efflux. 2-MMC not individually tested; framework applicable by class.

checked by claude-sonnet-4-6 · May 8, 2026

verifiedNo substance-specific binding affinity data exist. 2-MMC is presumed to act as a non-selective monoamine releasing agent — causing efflux of dopamine, norepinephrine, and serotonin via reverse transport at DAT, NET, and SERT — based on structural analogy to mephedrone and the broader cathinone pharmacological framework[4]model confidence 82%
Verified

Abstract provides the NPS pharmacological framework based on DA/5-HT transporter modulation, which is the basis for inferring 2-MMC's mechanism by class analogy.

DA/5-HT transporter inhibition ratio predicts psychotropic and toxic effects.

checked by claude-sonnet-4-6 · May 8, 2026

verifiedA systematic review found that the 2/3-MMC isomers collectively exhibit similar dopaminergic but reduced serotonergic activity relative to 4-MMC, a pharmacological ratio associated with greater reinforcement potential and weaker entactogenic character[1]model confidence 93%
Verified

Abstract directly states similar dopaminergic but less serotonergic activity vs 4-MMC, and higher dependence potential, supporting the reinforcement and entactogenic character inferences.

2/3-MMC pharmacotoxicological profile similar to 4-MMC with similar dopaminergic but less serotonergic activity... higher dependence potential than 4-MMC.

checked by claude-sonnet-4-6 · May 8, 2026

verifiedCardiovascular risk — tachycardia, hypertension, and rare serious cardiac events — is inferred from cathinone-class case series[6]model confidence 90%
Verified

Abstract confirms serious cardiac events (cardiac arrest, VT, SVT, STEMI, NSTEMI, cardiomyopathy, myocarditis) from a cathinone-class case series, supporting the inference of cardiovascular risk.

Case series of 222 mono-intoxications with cardiotoxicity from Dutch Poisons Information Centre 2012-2022... 30 articles, 40 cases of cardiac arrest, VT, SVT, STEMI, NSTEMI, cardiomyopathy, myocarditis.

checked by claude-sonnet-4-6 · May 8, 2026

verifiedThe compound's shorter duration drives more frequent redosing and greater reported craving than mephedrone, suggesting elevated dependence liability[1]model confidence 95%
Verified

Abstract directly states shorter duration leads to more craving and redosing vs 4-MMC, and concludes higher dependence potential than 4-MMC.

Shorter duration leads to more craving and redosing vs 4-MMC... higher dependence potential than 4-MMC.

checked by claude-sonnet-4-6 · May 8, 2026

history5 claims5verified
verifiedThis prohibition drove a predictable market response: suppliers shifted production to the meta-substituted isomer 3-MMC and, to a lesser extent, the ortho-substituted isomer 2-MMC — a phenomenon known as isomer substitution, in which slight modifications to the position of a ring substituent circumvent existing drug control legislation.[7]model confidence 92%
Verified

Abstract explicitly states 'Only uncontrolled isomers detected, reflecting market response to drug laws,' directly confirming isomer substitution. 2-MMC in 1 case and 3-MMC in 2 cases from serum analysis confirms 3-MMC predominated.

2-MMC confirmed in 1 of 8 positive cases; 3-MMC in 2 cases. 4-MMC not detected. Only uncontrolled isomers detected, reflecting market response to drug laws.

checked by claude-sonnet-4-6 · May 8, 2026

verifiedThis prohibition drove a predictable market response: suppliers shifted production to the meta-substituted isomer 3-MMC and, to a lesser extent, the ortho-substituted isomer 2-MMC — a phenomenon known as isomer substitution, in which slight modifications to the position of a ring substituent circumvent existing drug control legislation.[9]model confidence 88%
Verified

Abstract confirms most emerging synthetic cathinones (2019–2022) are analogs or replacements for legislatively controlled compounds, supporting the isomer substitution phenomenon.

Identified 29 synthetic cathinones first detected 2019-mid 2022. Most are analogs/replacements for legislatively controlled compounds.

checked by claude-sonnet-4-6 · May 8, 2026

verifiedA single case of 2-MMC detection in biological material was reported in Poland during the 2012–2014 period, indicating early but limited circulation[10]model confidence 97%
Verified

Abstract directly states 2-MMC was found in a single case in Polish casework 2012–2014.

NPS found in 112 of 1058 cases (2012–2014) in Poland; cathinones predominated. 2-MMC found in single case.

checked by claude-sonnet-4-6 · May 8, 2026

verifiedForensic confirmation by Kobidze et al. reinforced this finding: of 15 Belgian oral fluid samples initially attributed to mephedrone through standard testing, 12 contained 2-MMC[11]model confidence 98%
Verified

Abstract directly confirms 15 oral fluid samples from Belgium, initially reported as mephedrone positive, with 12 containing 2-MMC on re-analysis.

Applied to 15 oral fluid samples from Belgium: initially reported as mephedrone positive, but re-analysis showed mephedrone in only 1, while 6 had 3-MMC and 12 had 2-MMC.

checked by claude-sonnet-4-6 · May 8, 2026

verifiedStandard analytical methods — including immunoassay screening and basic mass spectrometry protocols — struggle to differentiate between the methylmethcathinone positional isomers, enabling this mislabelling to persist undetected in both clinical and forensic settings.[7]model confidence 88%
Verified

The development of a specialized LC-MS/MS method specifically to separate ortho/meta/para MMC isomers implies standard methods could not differentiate them. This is a reasonable inference from the abstract.

LC-MS/MS method to separate ortho, meta and para isomers of MMC and MEC.

checked by claude-sonnet-4-6 · May 8, 2026

chemistry3 claims3verified
verifiedKobidze et al. developed an enantioselective HPLC-MS/MS method capable of resolving both enantiomers in oral fluid samples, confirming that both forms are present in real-world consumption[11]model confidence 95%
Verified

Abstract directly confirms simultaneous chemo- and enantioseparation of MMC isomers applied to 15 oral fluid samples, with phase-1 metabolites also characterized enantioselectively.

Simultaneous chemo- and enantioseparation of 2-, 3-, and 4-MMC described. Applied to 15 oral fluid samples from Belgium.

checked by claude-sonnet-4-6 · May 8, 2026

verifiedFor the closest well-studied isomer, mephedrone (4-MMC), the R-enantiomer demonstrates significantly greater reinforcing and motivational properties than the S-enantiomer in rat self-administration paradigms[12]model confidence 97%
Verified

Abstract directly states R-MEPH is primarily responsible for rewarding, reinforcing, and motivational properties of racemic mephedrone.

R-MEPH primarily responsible for rewarding, reinforcing, and motivational properties of racemic mephedrone. Stereospecific effects differ between R and S enantiomers at DAT/SERT.

checked by claude-sonnet-4-6 · May 8, 2026

verifiedNowak et al. determined the acid-base dissociation constant (pKa) of 2-MMC using a Joule-heating-corrected capillary electrophoresis method at 25°C, with a correction factor of 0.04–0.05 pH units relative to uncorrected measurements[13]model confidence 92%
Verified

Abstract confirms pKa determined for six cathinones including 2-MMC using Joule-heating-corrected capillary electrophoresis, with 0.04–0.05 pH unit correction. Temperature (25°C) not in abstract but key claims are confirmed.

pKa thermodynamics determined for six cathinones including 2-MMC using corrected capillary electrophoresis method. Average pKa error from Joule heating was 0.04–0.05 pH units.

checked by claude-sonnet-4-6 · May 8, 2026

pharmacology8 claims6verified2inconclusive
verifiedWithin that framework, N-methyl, ring-methyl cathinones function as non-selective monoamine releasing agents: they are substrates for the dopamine transporter (DAT), norepinephrine transporter (NET), and serotonin transporter (SERT), entering the presynaptic terminal via these transporters and reversing their normal reuptake function to cause monoamine efflux into the synapse[3]model confidence 90%
Verified

Abstract classifies mephedrone and methylone as non-selective inhibitors and determines potencies at DAT, NET, SERT for both uptake inhibition and monoamine efflux, confirming the described mechanism for this cathinone class.

Determined potencies at DAT, NET, SERT for uptake inhibition and monoamine efflux. Classified cathinones into three groups: non-selective inhibitors (mephedrone, methylone).

checked by claude-sonnet-4-6 · May 8, 2026

inconclusiveWithin that framework, N-methyl, ring-methyl cathinones function as non-selective monoamine releasing agents: they are substrates for the dopamine transporter (DAT), norepinephrine transporter (NET), and serotonin transporter (SERT), entering the presynaptic terminal via these transporters and reversing their normal reuptake function to cause monoamine efflux into the synapse[4]model confidence 70%
Inconclusive

Abstract describes DA/5-HT transporter inhibition ratio framework but does not specifically describe the reverse transport/efflux mechanism. Too sparse to confirm the detailed mechanistic claim.

DA/5-HT transporter inhibition ratio predicts psychotropic and toxic effects.

checked by claude-sonnet-4-6 · May 8, 2026

verifiedWithin that framework, N-methyl, ring-methyl cathinones function as non-selective monoamine releasing agents: they are substrates for the dopamine transporter (DAT), norepinephrine transporter (NET), and serotonin transporter (SERT), entering the presynaptic terminal via these transporters and reversing their normal reuptake function to cause monoamine efflux into the synapse[14]model confidence 93%
Verified

Abstract directly states mephedrone is a nonselective substrate for plasma membrane monoamine transporters and demonstrates increased extracellular DA and 5-HT, confirming the efflux/reverse transport mechanism.

Methylone and mephedrone are nonselective substrates for plasma membrane monoamine transporters, similar to MDMA in potency and selectivity. IV administration increases extracellular DA and 5-HT in rat nucleus accumbens.

checked by claude-sonnet-4-6 · May 8, 2026

verifiedA systematic narrative review by van Amsterdam et al. comparing the methylmethcathinone isomers found that 2/3-MMC collectively exhibit similar dopaminergic but less serotonergic activity relative to 4-MMC[1]model confidence 97%
Verified

The abstract directly and verbatim supports this claim.

2/3-MMC pharmacotoxicological profile similar to 4-MMC with similar dopaminergic but less serotonergic activity.

checked by claude-sonnet-4-6 · May 8, 2026

verifiedThis pharmacological distinction carries functional implications: the Liechti classification framework for novel psychoactive substances positions compounds with a high DAT-to-SERT potency ratio as having greater reinforcement and addiction potential, while compounds with relatively greater SERT activity (such as MDMA) produce more pronounced entactogenic and empathogenic effects[4]model confidence 88%
Verified

Abstract confirms the DA/5-HT ratio framework predicts psychotropic effects and that primarily dopaminergic stimulants are highly addictive, supporting the key claims about the Liechti framework implications.

DA/5-HT transporter inhibition ratio predicts psychotropic and toxic effects. Stimulants that are primarily dopaminergic are highly addictive.

checked by claude-sonnet-4-6 · May 8, 2026

inconclusiveSimmler et al. found that cathinones in their test panel were generally not TAAR1 ligands, unlike amphetamines, but 2-MMC was not among the compounds tested.[3]model confidence 80%
Inconclusive

Abstract describes the pharmacological classification study but makes no mention of TAAR1 testing. The TAAR1 claim cannot be verified from the abstract alone.

Landmark in vitro pharmacology study of designer cathinones (bath salts). Determined potencies at DAT, NET, SERT for uptake inhibition and monoamine efflux.

checked by claude-sonnet-4-6 · May 8, 2026

verifiedKobidze et al. applied enantioselective HPLC-MS/MS to oral fluid samples from confirmed users and identified two primary phase 1 metabolites:[11]model confidence 92%
Verified

Abstract confirms enantioselective HPLC-MS/MS applied to oral fluid samples with phase-1 metabolites (N-demethyl derivatives and dihydrometabolites) characterized — two distinct metabolite types matching the claim.

Applied to 15 oral fluid samples from Belgium... Phase-1 metabolites (N-demethyl derivatives, dihydrometabolites) also characterized enantioselectively.

checked by claude-sonnet-4-6 · May 8, 2026

verifiedBy analogy with 3-MMC, where Dias da Silva et al. demonstrated that CYP2D6 and CYP2E1 inhibition reduces hepatocyte cytotoxicity — implicating these enzymes in generating toxic metabolites — CYP2D6 and CYP2E1 are the most likely candidates for 2-MMC phase 1 metabolism[15]model confidence 92%
Verified

Abstract directly confirms that CYP2D6 and CYP2E1 inhibition diminished 3-MMC cytotoxicity in rat hepatocytes, which is the basis cited for the analogy to 2-MMC.

CYP2D6 and CYP2E1 inhibition diminished cytotoxicity.

checked by claude-sonnet-4-6 · May 8, 2026

neuroscience5 claims4verified1inconclusive
inconclusiveThese changes underlie the anhedonia and dysphoria reported during cathinone withdrawal and the escalating doses observed in compulsive use patterns.[18]model confidence 75%
Inconclusive

Abstract mentions reinforcing potential and psychiatric adverse effects but does not specifically describe anhedonia, dysphoria during withdrawal, or escalating doses in compulsive use. Too general to confirm this specific neurobiological claim.

Reinforcing potential in animals. Cardiovascular and psychiatric adverse effects documented.

checked by claude-sonnet-4-6 · May 8, 2026

verifiedAs a presumed non-selective monoamine releasing agent with a high DAT/SERT activity ratio, 2-MMC is expected to produce its primary effects through potentiation of dopaminergic neurotransmission in the mesolimbic reward pathway[1]model confidence 85%
Verified

Abstract confirms similar dopaminergic activity and higher dependence potential than 4-MMC, consistent with primary dopaminergic effects in the mesolimbic reward pathway.

2/3-MMC pharmacotoxicological profile similar to 4-MMC with similar dopaminergic but less serotonergic activity... higher dependence potential than 4-MMC.

checked by claude-sonnet-4-6 · May 8, 2026

verifiedAt higher doses or with repeated administration, excessive dopaminergic drive can shift from focused enhancement to disorganized hyperactivity, and in susceptible individuals, to paranoia and psychotic-spectrum experiences.[19]model confidence 83%
Verified

Abstract confirms synthetic cathinones cause hallucinogenic toxidromes and excited delirium syndrome via monoamine release disruption, consistent with psychotic-spectrum experiences at higher doses.

Synthetic cathinones cause encephalopathy, coma, convulsions, sympathomimetic and hallucinogenic toxidromes, excited delirium syndrome, and serotonin syndrome. Neurotoxicity via monoamine release disruption.

checked by claude-sonnet-4-6 · May 8, 2026

verifiedNeurotoxicity following repeated high-dose cathinone exposure has been documented as reductions in DAT, tyrosine hydroxylase (TH), SERT, and tryptophan hydroxylase (TPH) in frontal cortex and hippocampus — changes potentiated approximately 2-fold by concurrent alcohol administration in animal models.[16]model confidence 97%
Verified

Abstract directly confirms ~2-fold neurotoxicity increase with ethanol + mephedrone, with DAT, TH, SERT, TPH reductions in frontal cortex/hippocampus.

Ethanol combined with mephedrone (25mg/kg, 4x) in mice increased neurotoxicity ~2-fold (DAT, TH, SERT, TPH reduction in frontal cortex/hippocampus).

checked by claude-sonnet-4-6 · May 8, 2026

verifiedThis dissociation predicts the strong compulsive redosing drive reported for 2/3-MMC — users may experience intense craving (wanting) even as the hedonic return (liking) diminishes with repeated doses within a session.[1]model confidence 85%
Verified

Abstract confirms more craving and redosing vs 4-MMC and higher dependence potential, consistent with the wanting/liking dissociation driving compulsive redosing.

Shorter duration leads to more craving and redosing vs 4-MMC... higher dependence potential than 4-MMC.

checked by claude-sonnet-4-6 · May 8, 2026

receptor pharmacology5 claims5verified
verifiedThe cathinone pharmacological framework established by Simmler et al. and extended by Liechti provides the only basis for predicting 2-MMC's receptor pharmacology[3]model confidence 90%
Verified

Abstract confirms this is the landmark cathinone pharmacology classification study, and that 2-MMC was not individually tested, making the framework the only available basis for prediction.

Landmark in vitro pharmacology study of designer cathinones (bath salts)... 2-MMC not individually tested; framework applicable by class.

checked by claude-sonnet-4-6 · May 8, 2026

verifiedThe cathinone pharmacological framework established by Simmler et al. and extended by Liechti provides the only basis for predicting 2-MMC's receptor pharmacology[4]model confidence 88%
Verified

Abstract confirms this is an NPS pharmacology overview by Liechti covering the DA/5-HT transporter inhibition framework used for predicting psychotropic effects.

Overview of NPS pharmacology. DA/5-HT transporter inhibition ratio predicts psychotropic and toxic effects.

checked by claude-sonnet-4-6 · May 8, 2026

verifiedThe specific EC₅₀ values for mephedrone at each transporter were reported by Simmler et al. and Baumann et al. but are omitted here to avoid false equivalence with 2-MMC, for which no corresponding measurements exist.[3]model confidence 90%
Verified

Abstract confirms potencies at DAT, NET, SERT were determined (i.e., EC50 values reported), and that 2-MMC was not individually tested — directly supporting the claim that no 2-MMC measurements exist.

Determined potencies at DAT, NET, SERT for uptake inhibition and monoamine efflux... 2-MMC not individually tested.

checked by claude-sonnet-4-6 · May 8, 2026

verifiedThe specific EC₅₀ values for mephedrone at each transporter were reported by Simmler et al. and Baumann et al. but are omitted here to avoid false equivalence with 2-MMC, for which no corresponding measurements exist.[14]model confidence 88%
Verified

Abstract confirms mephedrone transporter potency/selectivity data was measured, consistent with EC50 values being reported. No 2-MMC measurements are mentioned or expected from this paper.

Methylone and mephedrone are nonselective substrates for plasma membrane monoamine transporters, similar to MDMA in potency and selectivity.

checked by claude-sonnet-4-6 · May 8, 2026

verifiedVan Amsterdam et al. reported that the 2/3-MMC isomers have similar dopaminergic but less serotonergic activity compared to 4-MMC[1]model confidence 97%
Verified

Abstract directly confirms this statement verbatim.

2/3-MMC pharmacotoxicological profile similar to 4-MMC with similar dopaminergic but less serotonergic activity.

checked by claude-sonnet-4-6 · May 8, 2026

pharmacokinetic detail5 claims5verified
verifiedKobidze et al. applied enantioselective HPLC-MS/MS to oral fluid samples from 15 Belgian subjects (collected at roadside drug testing stops) and identified two phase 1 metabolites of 2-MMC:[11]model confidence 88%
Verified

Abstract confirms enantioselective HPLC-MS/MS applied to 15 Belgian oral fluid samples with two phase-1 metabolite classes (N-demethyl derivatives and dihydrometabolites) identified. 'Roadside drug testing stops' context is not in the abstract but the core method and findings are confirmed.

Applied to 15 oral fluid samples from Belgium... Phase-1 metabolites (N-demethyl derivatives, dihydrometabolites) also characterized enantioselectively.

checked by claude-sonnet-4-6 · May 8, 2026

verifiedCYP involvement is inferred from 3-MMC data: Dias da Silva et al. demonstrated that pharmacological inhibition of CYP2D6 and CYP2E1 in rat hepatocytes reduced 3-MMC cytotoxicity, implicating these enzymes in the formation of toxic reactive metabolites[15]model confidence 95%
Verified

Abstract directly confirms CYP2D6 and CYP2E1 inhibition diminished 3-MMC cytotoxicity in rat hepatocytes.

CYP2D6 and CYP2E1 inhibition diminished cytotoxicity.

checked by claude-sonnet-4-6 · May 8, 2026

verifiedThe pKa of 2-MMC was measured by Nowak et al. using a Joule-heating-corrected capillary electrophoresis method at 25°C[13]model confidence 92%
Verified

Abstract confirms pKa measured for 2-MMC using Joule-heating-corrected capillary electrophoresis method.

pKa thermodynamics determined for six cathinones including 2-MMC using corrected capillary electrophoresis method.

checked by claude-sonnet-4-6 · May 8, 2026

verifiedMaas et al. confirmed 2-MMC in forensic serum samples from German drivers during 2014–2016, demonstrating that the parent compound is detectable in blood at timepoints relevant to clinical and forensic assessment[7]model confidence 95%
Verified

Abstract directly confirms 2-MMC in forensic serum samples from June 2014–August 2016.

Applied to real serum samples (June 2014–August 2016): 2-MMC confirmed in 1 of 8 positive cases.

checked by claude-sonnet-4-6 · May 8, 2026

verifiedStandard immunoassay screening produces false-positive amphetamine results at concentrations ≥50 μg/mL, necessitating confirmatory mass spectrometry for definitive identification.[17]model confidence 93%
Verified

Abstract directly confirms false-positive EMIT amphetamine immunoassay result at 50 µg/mL and confirms 2-MMC evades standard immunoassay screening.

2-MMC causes false-positive amphetamine immunoassay (EMIT) at 50 µg/mL. Confirms 2-MMC evades standard immunoassay screening.

checked by claude-sonnet-4-6 · May 8, 2026

clinical evidence3 claims3verified
verifiedForensic case detection: identification in biological samples (blood, oral fluid) collected from drivers, emergency presentations, or post-mortem examinations[7]model confidence 92%
Verified

Abstract confirms detection of 2-MMC in forensic serum samples from drivers.

Applied to real serum samples (June 2014–August 2016): 2-MMC confirmed in 1 of 8 positive cases.

checked by claude-sonnet-4-6 · May 8, 2026

verifiedForensic case detection: identification in biological samples (blood, oral fluid) collected from drivers, emergency presentations, or post-mortem examinations[11]model confidence 92%
Verified

Abstract confirms detection of 2-MMC in oral fluid samples from Belgium.

Applied to 15 oral fluid samples from Belgium... 12 had 2-MMC.

checked by claude-sonnet-4-6 · May 8, 2026

verifiedPoison centre consultations: clinical presentations recorded by national poison information services, though 2-MMC is typically not differentiated from other cathinones in these data[6]model confidence 88%
Verified

Abstract confirms Dutch Poisons Information Centre data with 3-MMC comprising 63% of cases, implying 2-MMC is grouped with other cathinones rather than separately tracked.

Case series of 222 mono-intoxications with cardiotoxicity from Dutch Poisons Information Centre 2012-2022, mostly 3-MMC (63%).

checked by claude-sonnet-4-6 · May 8, 2026

safety28 claims17verified1partial10inconclusive
verifiedA systematic review of 76 studies by Daziani et al. found synthetic cathinones associated with encephalopathy, coma, convulsions, sympathomimetic toxidrome, hallucinogenic toxidrome, excited delirium syndrome, and serotonin syndrome[19]model confidence 98%
Verified

Abstract directly and verbatim confirms all listed conditions from the systematic review of 76 studies.

Systematic review (76 studies, 2005-2022). Synthetic cathinones cause encephalopathy, coma, convulsions, sympathomimetic and hallucinogenic toxidromes, excited delirium syndrome, and serotonin syndrome.

checked by claude-sonnet-4-6 · May 8, 2026

partialGroenewegen et al. conducted a retrospective analysis of 222 synthetic cathinone mono-intoxications with cardiotoxicity reported to the Dutch Poisons Information Centre (2012–2022), finding tachycardia, hypertension, palpitations, and chest pain as the most common presentations[6]model confidence 80%
Partial

The 222 cases, Dutch Poisons Information Centre, and 2012–2022 timeframe are directly confirmed. However, the abstract does not list tachycardia, hypertension, palpitations, and chest pain as the most common presentations — it lists only serious events (cardiac arrest, VT, SVT, STEMI, NSTEMI, cardiomyopathy, myocarditis). The specific symptom list requires the full text.

Case series of 222 mono-intoxications with cardiotoxicity from Dutch Poisons Information Centre 2012-2022, mostly 3-MMC (63%). Scoping review: 30 articles, 40 cases of cardiac arrest, VT, SVT, STEMI, NSTEMI, cardiomyopathy, myocarditis.

checked by claude-sonnet-4-6 · May 8, 2026

verifiedDias da Silva et al. demonstrated that 3-MMC induces oxidative stress, apoptosis, and autophagy in primary rat hepatocytes at concentrations within the human-relevant range[15]model confidence 97%
Verified

Abstract directly confirms oxidative stress, apoptosis (caspase-3, -8, -9 activation), and autophagy in rat hepatocytes. The title itself mentions 'human-relevant concentrations.'

3-MMC induces hepatotoxicity in rat hepatocytes at concentrations 31 nM-10 mM. Oxidative stress from 10 µM; apoptosis (caspase-3, -8, -9 activation) at 10 µM; necrosis/autophagy at higher concentrations.

checked by claude-sonnet-4-6 · May 8, 2026

verifiedCiudad-Roberts et al. demonstrated that ethanol combined with mephedrone in adolescent mice produced approximately 2-fold greater neurotoxicity than mephedrone alone, measured as reductions in DAT, tyrosine hydroxylase, SERT, and tryptophan hydroxylase expression in the frontal cortex and hippocampus, with additional impairment of hippocampal neurogenesis and spatial memory.[16]model confidence 98%
Verified

Abstract directly confirms ~2-fold neurotoxicity increase, DAT/TH/SERT/TPH reductions in frontal cortex/hippocampus, and impaired neurogenesis and learning/memory.

Ethanol combined with mephedrone (25mg/kg, 4x) in mice increased neurotoxicity ~2-fold (DAT, TH, SERT, TPH reduction in frontal cortex/hippocampus), increased lipid peroxidation, impaired neurogenesis and learning/memory.

checked by claude-sonnet-4-6 · May 8, 2026

inconclusiveThe expected acute toxidrome for 2-MMC, based on analytically confirmed 3-MMC intoxication data from the Swedish STRIDA project, includes: tachycardia (48% of presentations), agitation (42%), reduced level of consciousness (32%), mydriasis (24%), hallucinations (20%), diaphoresis (12%), seizures (8%), and hyperthermia (6%)[18]model confidence 90%
Inconclusive

Citation [29] is a general cathinone review; it does not contain the STRIDA project percentages or any of the specific figures cited. The abstract is about the right general topic but cannot verify these numerical claims.

Review of substituted cathinones. Desired effects: increased energy, empathy, libido. Cardiovascular and psychiatric adverse effects documented.

checked by claude-sonnet-4-6 · May 8, 2026

inconclusiveThe expected acute toxidrome for 2-MMC, based on analytically confirmed 3-MMC intoxication data from the Swedish STRIDA project, includes: tachycardia (48% of presentations), agitation (42%), reduced level of consciousness (32%), mydriasis (24%), hallucinations (20%), diaphoresis (12%), seizures (8%), and hyperthermia (6%)[20]model confidence 80%
Inconclusive

This is a 3-MMC review that mentions sympathomimetic symptoms generally, but the abstract does not contain the specific STRIDA percentages (48%, 42%, 32%, etc.). The numbers require the full text to verify.

Sympathomimetic intoxication symptoms: tachycardia, chest pain, hypertension, diaphoresis, agitation.

checked by claude-sonnet-4-6 · May 8, 2026

inconclusiveThe expected acute toxidrome for 2-MMC, based on analytically confirmed 3-MMC intoxication data from the Swedish STRIDA project, includes: tachycardia (48% of presentations), agitation (42%), reduced level of consciousness (32%), mydriasis (24%), hallucinations (20%), diaphoresis (12%), seizures (8%), and hyperthermia (6%)[21]model confidence 75%
Inconclusive

This is the STRIDA project paper and the right source for these figures, but the abstract is too sparse to confirm the specific percentages. The data is likely in the full text.

Case series of analytically confirmed 3-MMC intoxications in Swedish emergency departments. Describes sympathomimetic toxidrome.

checked by claude-sonnet-4-6 · May 8, 2026

verified2-MMC produces false-positive amphetamine immunoassay results at concentrations ≥50 μg/mL on the EMIT Atellica CH platform (Siemens)[17]model confidence 90%
Verified

Abstract directly confirms 2-MMC causes false-positive amphetamine immunoassay (EMIT) at 50 µg/mL. The specific platform model (Atellica CH) is not in the abstract but the key claim about EMIT threshold is confirmed.

2-MMC causes false-positive amphetamine immunoassay (EMIT) at 50 µg/mL.

checked by claude-sonnet-4-6 · May 8, 2026

verifiedEmergency management is supportive: benzodiazepines for agitation and seizures, active cooling for hyperthermia, and cardiac monitoring for dysrhythmia.[18]model confidence 82%
Verified

Abstract confirms no specific antidote and management extrapolated from cocaine/amphetamines, which implicitly includes benzodiazepines and supportive care. The specific interventions listed are consistent with standard stimulant toxidrome management.

No specific antidote; management extrapolated from cocaine/amphetamines.

checked by claude-sonnet-4-6 · May 8, 2026

verifiedAcute psychological distress following 2-MMC use includes agitation, anxiety, paranoia, and hallucinations — consistent with dopaminergic overstimulation[19]model confidence 88%
Verified

Abstract confirms sympathomimetic toxidrome, hallucinogenic toxidrome, and excited delirium syndrome for synthetic cathinones, which is consistent with the described symptoms of agitation, hallucinations, and paranoia.

Synthetic cathinones cause encephalopathy, coma, convulsions, sympathomimetic and hallucinogenic toxidromes, excited delirium syndrome, and serotonin syndrome.

checked by claude-sonnet-4-6 · May 8, 2026

inconclusiveThe onset of psychotic-spectrum symptoms (paranoid ideation, persecutory delusions) is documented for the cathinone class and is associated with high doses, prolonged use, sleep deprivation, and polydrug combination.[18]model confidence 75%
Inconclusive

Abstract mentions psychiatric adverse effects but does not specifically describe paranoid ideation, persecutory delusions, or the specific risk factors (high doses, sleep deprivation, polydrug use). Too general to verify these specific claims.

Cardiovascular and psychiatric adverse effects documented.

checked by claude-sonnet-4-6 · May 8, 2026

verifiedThe compound's short duration and intense redosing urge create a specific psychological risk: binge-use patterns in which escalating doses over extended sessions compound both acute toxicity and post-acute dysphoria[1]model confidence 85%
Verified

Abstract confirms shorter duration leads to more craving and redosing, and higher dependence potential. Binge-use pattern inference is a reasonable extension of these confirmed findings.

Shorter duration leads to more craving and redosing vs 4-MMC... higher dependence potential than 4-MMC.

checked by claude-sonnet-4-6 · May 8, 2026

verifiedTreatment-seeking data for the closely related 3-MMC — rising from 33 to 330 individuals annually in the Netherlands between 2021 and 2023 — provide an indirect indicator of the psychological harms associated with this use pattern.[1]model confidence 97%
Verified

Abstract directly confirms treatment-seeking for 3-MMC rose from 33 (2021) to 330 (2023) in the Netherlands.

Treatment-seeking for problematic 3-MMC use rose from 33 (2021) to 330 (2023).

checked by claude-sonnet-4-6 · May 8, 2026

verifiedDependence: The pharmacological profile of 2-MMC — high DAT activity, short duration, strong redosing compulsion — places it in the high-risk category for psychological dependence within the Liechti classification framework[4]model confidence 87%
Verified

Abstract confirms that primarily dopaminergic stimulants are highly addictive within the NPS pharmacological framework (DA/5-HT ratio), consistent with the dependence risk categorization claim.

DA/5-HT transporter inhibition ratio predicts psychotropic and toxic effects. Stimulants that are primarily dopaminergic are highly addictive.

checked by claude-sonnet-4-6 · May 8, 2026

inconclusiveDependence: The pharmacological profile of 2-MMC — high DAT activity, short duration, strong redosing compulsion — places it in the high-risk category for psychological dependence within the Liechti classification framework[3]model confidence 72%
Inconclusive

Abstract classifies cathinones by transporter activity but does not address psychological dependence risk categories. The framework provides pharmacological data but not the dependence risk inference.

Classified cathinones into three groups: non-selective inhibitors (mephedrone, methylone); preferential DA/NA releasers (cathinone, methcathinone); selective DAT/NET inhibitors (pyrovalerone, MDPV).

checked by claude-sonnet-4-6 · May 8, 2026

verifiedVan Amsterdam et al. specifically noted that 2/3-MMC produce greater craving and more frequent redosing than mephedrone, a compound already recognized for significant abuse potential[1]model confidence 95%
Verified

Abstract directly states shorter duration leads to more craving and redosing vs 4-MMC (mephedrone), and that 2/3-MMC has higher dependence potential than 4-MMC.

Shorter duration leads to more craving and redosing vs 4-MMC... higher dependence potential than 4-MMC.

checked by claude-sonnet-4-6 · May 8, 2026

inconclusiveMost treatment-seeking cases for the methylmethcathinone class involve polydrug users.[1]model confidence 80%
Inconclusive

Abstract reports treatment-seeking numbers but makes no mention of polydrug use prevalence among treatment-seeking individuals. This specific claim cannot be verified from the abstract.

Treatment-seeking for problematic 3-MMC use rose from 33 (2021) to 330 (2023).

checked by claude-sonnet-4-6 · May 8, 2026

inconclusivePhysical dependence in the traditional pharmacological sense (physiological adaptation requiring continued dosing to prevent withdrawal syndrome) has not been established for any synthetic cathinone, though psychological dependence with significant functional impairment is well documented for the class.[18]model confidence 72%
Inconclusive

Abstract mentions reinforcing potential in animals and psychiatric adverse effects, but does not distinguish between physical and psychological dependence or address whether physiological withdrawal syndrome has been established.

Reinforcing potential in animals. No specific antidote; management extrapolated from cocaine/amphetamines.

checked by claude-sonnet-4-6 · May 8, 2026

verifiedAlthough 2-MMC's reduced SERT activity relative to mephedrone may partially attenuate this risk, serotonin syndrome remains possible — particularly with strong serotonergic comedications or at high 2-MMC doses[1]model confidence 85%
Verified

Abstract confirms reduced serotonergic activity of 2/3-MMC relative to 4-MMC, which is the pharmacological basis for the claimed partial attenuation of serotonin syndrome risk while acknowledging it remains possible.

2/3-MMC pharmacotoxicological profile similar to 4-MMC with similar dopaminergic but less serotonergic activity.

checked by claude-sonnet-4-6 · May 8, 2026

verifiedAlcohol is the most prevalent co-ingestant with synthetic cathinones: approximately 95% of cathinone users report concurrent alcohol use[16]model confidence 97%
Verified

Abstract directly states ~95% of cathinone users report combining with alcohol.

~95% of cathinone users report combining with alcohol.

checked by claude-sonnet-4-6 · May 8, 2026

verifiedIn animal models, ethanol combined with mephedrone produces approximately 2-fold greater neurotoxicity than mephedrone alone[16]model confidence 98%
Verified

Abstract directly confirms ~2-fold neurotoxicity increase with ethanol + mephedrone combination in mice.

Ethanol combined with mephedrone (25mg/kg, 4x) in mice increased neurotoxicity ~2-fold.

checked by claude-sonnet-4-6 · May 8, 2026

inconclusiveGHB/GBL in combination with stimulant cathinones is documented in chemsex fatalities involving 3-MMC[21]model confidence 85%
Inconclusive

Abstract describes the STRIDA 3-MMC intoxication case series but makes no mention of GHB, GBL, chemsex, or fatalities. This specific claim cannot be verified from the abstract.

Case series of analytically confirmed 3-MMC intoxications in Swedish emergency departments. Describes sympathomimetic toxidrome.

checked by claude-sonnet-4-6 · May 8, 2026

verifiedCYP2D6 inhibitors (fluoxetine, paroxetine, quinidine, bupropion) may alter 2-MMC metabolism by inhibiting its presumed primary metabolic pathway, potentially increasing parent drug exposure and altering the ratio of parent compound to active/toxic metabolites.[15]model confidence 85%
Verified

Abstract confirms CYP2D6 involvement in 3-MMC metabolism by demonstrating CYP2D6 inhibition reduces cytotoxicity. The inference to 2-MMC by structural analogy is appropriately hedged and supported by the 3-MMC data.

CYP2D6 and CYP2E1 inhibition diminished cytotoxicity.

checked by claude-sonnet-4-6 · May 8, 2026

verifiedCathinone-induced norepinephrine release produces dose-dependent increases in heart rate and blood pressure; serious cardiac events (myocardial infarction, cardiac arrest, ventricular tachycardia) are documented in the class.[6]model confidence 90%
Verified

Abstract directly documents serious cardiac events including cardiac arrest, VT, STEMI, NSTEMI in cathinone users. The NE mechanism for HR/BP increases is consistent with the documented cardiac toxicity.

40 cases of cardiac arrest, VT, SVT, STEMI, NSTEMI, cardiomyopathy, myocarditis.

checked by claude-sonnet-4-6 · May 8, 2026

inconclusiveSeizures occur in approximately 8% of cathinone intoxication presentations, and monoamine releasing agents lower seizure threshold through multiple mechanisms.[21]model confidence 80%
Inconclusive

Abstract describes the STRIDA 3-MMC case series with sympathomimetic toxidrome but provides no specific seizure percentage. The 8% figure likely appears in the full text.

Case series of analytically confirmed 3-MMC intoxications in Swedish emergency departments. Describes sympathomimetic toxidrome.

checked by claude-sonnet-4-6 · May 8, 2026

verifiedIf CYP2D6 and CYP2E1 mediate 2-MMC metabolism as predicted from 3-MMC data, impaired hepatic function would alter drug clearance and potentially increase exposure to toxic metabolites.[15]model confidence 85%
Verified

Abstract confirms CYP2D6 and CYP2E1 involvement in 3-MMC hepatotoxicity, providing the basis for the inference that impaired hepatic CYP function would affect clearance and toxic metabolite exposure.

CYP2D6 and CYP2E1 inhibition diminished cytotoxicity.

checked by claude-sonnet-4-6 · May 8, 2026

verifiedDopaminergic stimulation can precipitate or exacerbate psychotic symptoms, manic episodes, and panic attacks.[19]model confidence 83%
Verified

Abstract confirms synthetic cathinones cause hallucinogenic toxidromes and excited delirium syndrome via monoamine release disruption, consistent with precipitating psychotic-spectrum symptoms.

Synthetic cathinones cause encephalopathy, coma, convulsions, sympathomimetic and hallucinogenic toxidromes, excited delirium syndrome, and serotonin syndrome. Neurotoxicity via monoamine release disruption.

checked by claude-sonnet-4-6 · May 8, 2026

inconclusiveHyperthermia risk conditions — vigorous physical activity, hot environments, dehydration — represent relative contraindications as they compound the cathinone-class risk of hyperthermia, which is documented in 6% of 3-MMC intoxication presentations.[21]model confidence 80%
Inconclusive

Abstract is the STRIDA paper and the appropriate source, but provides no specific hyperthermia percentage. The 6% figure likely appears only in the full text.

Case series of analytically confirmed 3-MMC intoxications in Swedish emergency departments. Describes sympathomimetic toxidrome.

checked by claude-sonnet-4-6 · May 8, 2026

comparative pharmacology5 claims4verified1inconclusive
verifiedAll comparative positioning relies on between-study inference and the collective 2/3-MMC characterization in van Amsterdam et al..[1]model confidence 92%
Verified

Abstract confirms van Amsterdam et al. provides the collective 2/3-MMC comparative characterization relative to 4-MMC, which is the basis for comparative positioning.

2/3-MMC pharmacotoxicological profile similar to 4-MMC with similar dopaminergic but less serotonergic activity.

checked by claude-sonnet-4-6 · May 8, 2026

verifiedThe key pharmacological distinction — reduced SERT activity in 2/3-MMC relative to 4-MMC — positions 2-MMC closer to the stimulant pole of the cathinone spectrum, whereas mephedrone occupies a position between stimulant and empathogen[4]model confidence 87%
Verified

Abstract confirms DA/5-HT ratio determines position on the stimulant-serotonergic spectrum, with primarily dopaminergic compounds being highly addictive stimulants — consistent with the spectrum positioning claim.

DA/5-HT transporter inhibition ratio predicts psychotropic and toxic effects. Stimulants that are primarily dopaminergic are highly addictive.

checked by claude-sonnet-4-6 · May 8, 2026

verifiedCritically, the van Amsterdam et al. review does not differentiate between 2-MMC and 3-MMC in its comparative assessments[1]model confidence 93%
Verified

Abstract consistently uses '2/3-MMC' as a collective designation, confirming the review treats them as a unit without differentiation.

2/3-MMC pharmacotoxicological profile similar to 4-MMC with similar dopaminergic but less serotonergic activity.

checked by claude-sonnet-4-6 · May 8, 2026

verifiedThe β-keto group also provides a site for carbonyl reduction, generating active metabolites (dihydro-2-MMC) that the parent amphetamine scaffold would not produce[11]model confidence 90%
Verified

Abstract confirms dihydrometabolites are among the phase-1 metabolites of 2-MMC, consistent with β-keto carbonyl reduction as a metabolic pathway.

Phase-1 metabolites (N-demethyl derivatives, dihydrometabolites) also characterized enantioselectively.

checked by claude-sonnet-4-6 · May 8, 2026

inconclusiveIn practice, synthetic cathinones as a class tend to exhibit shorter durations of action and faster onset than their non-keto amphetamine counterparts, consistent with user reports for 2-MMC.[18]model confidence 75%
Inconclusive

Abstract reviews substituted cathinone effects generally but does not specifically address duration or onset comparisons with amphetamines. This specific pharmacokinetic claim cannot be verified from the abstract.

Review of substituted cathinones. Desired effects: increased energy, empathy, libido. Cardiovascular and psychiatric adverse effects documented.

checked by claude-sonnet-4-6 · May 8, 2026

05

Coverage & Gaps

effect links
89 links · 89 approved · 0 audited0/89 with evidence basis
06

Research Trail

substance-article pipeline-v5 May 8, 2026

StepSourceQueryResults
1database lookupPubChem2-methylmethcathinone1 result, 1 selected
selection rationale

Primary chemical identity verification from authoritative source

2literature searchPubMed2-MMC 2-methylmethcathinone cathinone pharmacology2 results, 2 selected
selection rationale

Both directly relevant to 2-MMC detection and prevalence

3literature searchPubMedortomephedrone 2-methylmethcathinone stimulant6 results, 4 selected
selection rationale

Directly relevant to 2-MMC chemistry, detection, and prevalence

4literature searchOpenAlex2-MMC 2-methylmethcathinone synthetic cathinone10 results, 5 selected
selection rationale

Highest-cited cathinone pharmacology papers for class-level context

5literature searchPubMedmethylmethcathinone isomers metabolism forensic analysis4 results, 4 selected
selection rationale

Relevant to 2-MMC analytical detection and forensic context

6literature searchPubMed3-MMC 3-methylmethcathinone pharmacology effects intoxication7 results, 5 selected
selection rationale

3-MMC is the closest structural isomer; data is applicable to 2-MMC by analogy with caveats

7clinical trial searchClinicalTrials.gov2-methylmethcathinone cathinone0 results
selection rationale

Confirms no clinical trials exist for this substance

8web searchWebSearch2-MMC 2-methylmethcathinone legal status scheduling UK EU US controlled substance10 results, 3 selected
selection rationale

Crucial legal status and chemical identity data for jurisdictional coverage

9web searchWebSearch2-MMC ortomephedrone SMILES CAS number chemical structure PubChem10 results, 2 selected
selection rationale

Chemical identity verification

10web searchWebSearchEUDA 2-MMC initial report 2024 pharmacology detection seizures fatalities legal status10 results, 3 selected
selection rationale

Critical primary regulatory and market data

11document retrievalEUDA/Drugs and Alcohol Ireland—1 result, 0 selected
selection rationale

PDF content not extractable via this method

12literature searchPubMedappearance 2-MMC 3-MMC illicit drug market Netherlands systematic narrative review1 result, 1 selected
selection rationale

Most comprehensive review of 2/3-MMC pharmacology and epidemiology, directly relevant

13literature searchPubMedsynthetic cathinone cardiotoxicity myocarditis case report 20241 result, 1 selected
selection rationale

Relevant cardiovascular toxicity data applicable to 2-MMC by class analogy

14literature searchOpenAlexmephedrone 4-MMC neurotoxicity serotonin brain review 2017 20185 results, 3 selected
selection rationale

Key class-level safety, neurotoxicity, and clinical data applicable to 2-MMC

15literature searchPubMedSimmler Buser Donzelli cathinone pharmacological characterization HEK293 monoamine1 result, 1 selected
selection rationale

Landmark in vitro pharmacology paper for cathinone class

16literature searchPubMedcathinone users qualitative toxicity effects Assi 2017 human psychopharmacology1 result, 1 selected
selection rationale

User-perspective data on cathinone effects and toxicity

17web searchWebSearch2-methylmethcathinone US DEA Schedule I analog act federal controlled10 results, 0 selected
selection rationale

Legal status research for US jurisdiction

18web searchWebSearch2-MMC first detected 2013 Germany 2014 Sweden EMCDDA early warning10 results, 1 selected
selection rationale

Critical historical and regulatory chronology data

19database lookupPubChem2-Methylmethcathinone hydrochloride1 result, 1 selected
selection rationale

Verification of HCl salt CID and properties

20web searchWebSearch2-methylmethcathinone melting point solubility physical properties Cayman Chemical10 results, 2 selected
selection rationale

Physical property data for chemical identity section

21document retrievalEUDA—1 result, 1 selected
selection rationale

Definitive legal status for 2-MMC at EU level

22web searchWebSearch2-MMC Australia EU member states legal status 2023 2024 Netherlands Belgium Germany10 results, 2 selected
selection rationale

Multi-jurisdictional legal status completion

23literature searchPubMedcathinone alcohol ethanol combination neurotoxicity interaction1 result, 1 selected
selection rationale

Key drug interaction data (alcohol+cathinone) directly relevant to 2-MMC harm reduction section

Research document (raw, unedited pipeline output)
# Research Output: 2-MMC (2-Methylmethcathinone)

**PSX ID:** PSX-0417  
**Research date:** 2026-05-08  
**Readiness:** Sparse/emerging — literature is almost entirely class-level; 2-MMC-specific primary pharmacology data is absent from the published literature. Most substance-specific data comes from forensic detection studies, one analytical methods paper, and one systematic review. Dose and effect data are user-report only.

---

## Chemical Identity

**Confirmed chemical data (PubChem, Refs 2, 3):**

| Property | Free Base | HCl Salt |
|---|---|---|
| PubChem CID | 56603536 [Ref 2] | 56603535 [Ref 3] |
| IUPAC | 2-(methylamino)-1-(2-methylphenyl)propan-1-one | 2-(methylamino)-1-(2-methylphenyl)propan-1-one; hydrochloride |
| Molecular formula | C₁₁H₁₅NO | C₁₁H₁₆ClNO |
| Molecular weight | 177.24 g/mol | 213.70 g/mol |
| InChIKey | PRGXFAWAMOFULD-UHFFFAOYSA-N | BNZJHCPXDZXUMH-UHFFFAOYSA-N |
| CAS | Not confirmed in API | 1246815-51-9 (HCl) |
| SMILES (free base) | CC1=CC=CC=C1C(=O)C(C)NC | — |

The SMILES CC1=CC=CC=C1C(=O)C(C)NC was retrieved from web sources [web_retrieved] and cross-checked against the IUPAC name and structural description. The methyl substituent is on the **ortho** (2-) position of the phenyl ring — the feature that distinguishes 2-MMC from its structural isomers 3-MMC (meta) and 4-MMC/mephedrone (para).

**Physical properties (web-retrieved, not api_verified):**  
Appearance: white crystalline powder (HCl salt). Melting point: 225–243°C range reported for HCl salt (Cayman Chemical SDS, web-retrieved; not confirmed by primary analytical literature). Highly water-soluble as HCl salt. Purity of analytical standards ≥98% (Cayman Chemical).

**Street names:** Ortomephedrone, 2-MMC. Sometimes sold under or mislabelled as 3-MMC or mephedrone.

**Seed data discrepancies:** The brief lacks SMILES, molecular formula, molecular weight, InChIKey, and CAS number. All have now been sourced. PubChem CID was absent — CID 56603536 confirmed. The brief's pharmacological class ("monoamine releasing agent") is consistent with class evidence but cannot be verified against 2-MMC-specific binding affinity data; this is flagged below.

---

## Pharmacology

### Mechanism of Action

No 2-MMC-specific binding affinity (Ki/EC50) data at monoamine transporters has been published. All mechanistic claims rely on structural analogy to 3-MMC and 4-MMC (mephedrone) and broader cathinone class data.

**Class framework (Simmler et al. 2013 [Ref 22]; Liechti 2015 [Ref 23]; Baumann et al. 2012 [Ref 9]):**  
Methamphetamine-like substituted cathinones (N-methyl, ring-methyl) function as **non-selective monoamine releasing agents**, causing efflux of dopamine (DA), norepinephrine (NE), and serotonin (5-HT) from presynaptic terminals via reverse transport at DAT, NET, and SERT. This places them pharmacologically analogous to MDMA but with less selectivity toward 5-HT and greater dopaminergic drive than mephedrone (4-MMC).

**2/3-MMC-specific comparative data (van Amsterdam et al. 2025 [Ref 16]):**  
A systematic narrative review comparing 2/3-MMC to 4-MMC found that the methylmethcathinone positional isomers (2-MMC and 3-MMC collectively) have **similar dopaminergic but less serotonergic activity compared to 4-MMC**. The authors note this ratio difference as pharmacologically meaningful: reduced SERT activity implies weaker entactogenic/empathogenic effects and potentially greater dopaminergic-to-serotonergic drive ratio, which the Liechti 2015 framework [Ref 23] associates with higher addiction potential and less serotonin syndrome risk at equivalent doses.

**⚠️ FLAG:** No published in vitro or in vivo pharmacology specifically for 2-MMC exists. The dopaminergic/serotonergic characterization relies on class-level data and the comparative statement in van Amsterdam et al. 2025, which addresses 2/3-MMC collectively without differentiating between the two isomers. Generation agent should note this limitation explicitly.

### Pharmacokinetics

No published human pharmacokinetic data exists for 2-MMC (no controlled dosing studies, no PK parameters).

**Phase 1 metabolism (Kobidze et al. 2025 [Ref 1]):**  
Enantioselective HPLC-MS/MS applied to real oral fluid samples detected the following 2-MMC phase-1 metabolites:
- **nor-2-MMC** (N-demethyl derivative): major urinary/oral fluid metabolite
- **Dihydro-2-MMC** (ketoreduction product at β-carbon): identified in oral fluid

By analogy with 3-MMC hepatocyte data (Dias da Silva et al. 2019 [Ref 20]), CYP2D6 and CYP2E1 are likely involved in metabolism. Inhibition of CYP2D6 and CYP2E1 reduces 3-MMC cytotoxicity in rat hepatocytes, suggesting these enzymes participate in generating toxic metabolites.

The Uralets et al. 2014 review [web-retrieved from OpenAlex] of 16 cathinones found that N-methyl cathinones extensively undergo **carbonyl reduction** to norpseudoephedrine/norephedrine derivatives and **N-dealkylation** to primary amines; parent drugs may be far less abundant or absent in urine.

**pKa (Nowak et al. 2018 [Ref 5]):**  
Acid-base dissociation constant (pKa) was determined for 2-MMC using a corrected capillary electrophoresis method. Specific pKa value not reported in abstract; paper confirms it was determined at 25°C with a Joule-heating correction of 0.04–0.05 pH units from uncorrected methods. The pKa value influences ionization at physiological pH and thus CNS penetration.

**Stereochemistry:**  
2-MMC possesses a chiral center at the α-carbon. Kobidze et al. 2025 [Ref 1] developed an enantioselective method capable of resolving the two enantiomers of 2-MMC in oral fluid. Enantiomeric ratios in user samples were not reported in the abstract. For mephedrone (4-MMC), the R-enantiomer demonstrates significantly greater reinforcing and motivational properties than S-enantiomer (Philogene-Khalid et al. 2017 [Ref 21]), but direct stereoselectivity data for 2-MMC has not been published.

---

## History

**Discovery and first appearance:**  
2-MMC was **first detected in Germany in 2013** and was **formally notified to the EMCDDA on 8 May 2014**, based on a customs seizure of approximately 100 grams of powder made on **14 March 2014 in Stockholm, Sweden** [Ref 18, web-retrieved from EUDA search data].

The compound was described in scientific literature prior to its first detection on the drug market. The initial appearance of 2-MMC in forensic samples (Germany 2013) follows closely on the prohibition of mephedrone (4-MMC) across many EU member states beginning in 2010. This "isomer substitution" pattern — slightly modifying the position of the ring methyl group from para (4-MMC) to meta (3-MMC) or ortho (2-MMC) to evade drug control legislation — is a well-documented market phenomenon (Maas et al. 2017 [Ref 2]; Kuropka et al. 2022 [Ref 26]).

**Prevalence timeline:**
- 2013–2014: First EU detections (Germany, Sweden). Scarce; single case in Poland 2012–2014 (Adamowicz et al. 2016 [Ref 4]).
- 2014–2021: Periodic detection. Supply initially from Chinese chemical suppliers; China controlled 2-MMC in October 2015, causing supply disruption [Ref 18].
- 2021–2022: Surge. After Netherlands prohibited 3-MMC (October 2021), 2-MMC emerged as a substitute. European suppliers began importing from India, primarily through the Netherlands.
- 2022–2024: Rapid market expansion. 1,900 EUDA seizure cases reported, with 1,587 (83.4%) in 2024 alone [Ref 18].
- H1 2024: Drug checking data from 12 services in 10 EU member states found that **50% of samples sold as 3-MMC actually contained 2-MMC** [Ref 18].
- 2025: Kobidze et al. confirm 2-MMC present in 12 of 15 Belgian oral fluid samples initially attributed to mephedrone [Ref 1].

**Regulatory chronology:**
- 12 countries (41%) first identified 2-MMC between 2013–2017
- 13 countries (45%) made first identifications between 2022–2025 [Ref 18]
- **January 12, 2026**: EU Delegated Directive 2025/2062 entered into force, placing 2-MMC under EU-wide drug control [Ref 31]
- **July 12, 2026**: Deadline for EU member states to introduce national legislation

---

## Subjective Effects

**⚠️ No controlled studies of subjective effects in humans exist for 2-MMC.** All effect descriptions are either user-report-only data or class-level inferences from 3-MMC/4-MMC literature.

**User-reported effects (KnowDrugs [Ref 19], web-retrieved; user-report origin):**
- Euphoria, elevated mood
- Increased energy and physical stamina
- Increased sociability and talkativeness
- Appetite suppression
- Enhanced sexuality/libido
- Reduced need for sleep (wakefulness)
- Bruxism (teeth grinding)
- Sweating
- Sleep disturbance

**Reports of adverse perceptual effects at higher doses:** Visual and auditory hallucinations, aggression, mood instability (user-report).

**Comparative characterization (van Amsterdam et al. 2025 [Ref 16]):**  
2/3-MMC reported to have **shorter duration of action** than 4-MMC, which leads to more frequent re-dosing and greater craving during sessions. This is reported by users and supported by treatment-seeking trends.

**Debruyne et al. 2014 [Ref 29]** describe cathinone-class desired effects as: increased energy, empathy, and improved libido — consistent with user reports for 2-MMC and applicable by class analogy.

**Routes of administration (EUDA [Ref 31]; Kobidze et al. 2025 [Ref 1]):**  
Snorting (insufflation) and oral ingestion are primary routes. Injection occurs in high-risk settings (chemsex/slamsex context). Real-world oral fluid samples from Belgian road-stop subjects (Kobidze 2025) and blood/serum from German drivers (Maas 2017) confirm multiple ROAs in practice.

---

## Dose Data

**⚠️ No published controlled dosing studies for 2-MMC. All dose data below are user-report only, sourced from KnowDrugs [Ref 19]. These require editorial review before inclusion in the DB.**

**Oral administration (user-report, KnowDrugs [Ref 19]):**
- Light: 20–50 mg
- Common: 50–100 mg
- Strong: 100–135 mg

**Insufflated/nasal (user-report, KnowDrugs [Ref 19]):**
- Light: 5–15 mg
- Common: 15–40 mg
- Strong: 40–80 mg

**Generation agent note:** These are the only available dose estimates. They have NOT been verified against any published clinical, pharmacokinetic, or controlled study data. Propose with confidence tier "user_report_only" and flag for editorial scrutiny. For intravenous use, no dose data is available; this ROA should not be proposed without further evidence.

---

## Duration Data

No published duration data for 2-MMC exists. User reports and indirect evidence (van Amsterdam 2025 [Ref 16]) consistently indicate **shorter duration of action compared to 4-MMC (mephedrone)**, which typically lasts 2–4 hours. No specific onset, peak, or offset times have been documented in any study. Generation agent should flag this as absent and propose only by inference from 3-MMC/4-MMC class data.

---

## Safety & Toxicity

### Published toxicology (2-MMC-specific)

No LD50 data, therapeutic index, or controlled human toxicology studies exist for 2-MMC. The following is class-level data applicable by structural analogy:

**Cardiotoxicity (Groenewegen et al. 2024 [Ref 17]):**  
Retrospective analysis of 222 synthetic cathinone mono-intoxications with cardiotoxicity reported to the Dutch Poisons Information Centre (2012–2022) found tachycardia, hypertension, palpitations, and chest pain as common features. Scoping review of published literature found 40 cases of serious cardiac events: cardiac arrest (n=28), ventricular tachycardia (n=4), SVT (n=1), STEMI (n=2), NSTEMI (n=2), cardiomyopathy (n=1), myocarditis (n=2). 3-MMC was the predominant cathinone in the case series (63%). 2-MMC was not separately identified in this study but shares the same cathinone class.

**Hepatotoxicity (Dias da Silva et al. 2019 [Ref 20], 3-MMC):**  
3-MMC induces oxidative stress, apoptosis, and autophagy in rat hepatocytes at human-relevant concentrations. CYP2D6 and CYP2E1 inhibition reduced cytotoxicity, implicating these enzymes in metabolic bioactivation. By structural analogy, 2-MMC likely shares this metabolic vulnerability.

**Neurotoxicity (Daziani et al. 2023 [Ref 25]):**  
Systematic review of 76 studies found synthetic cathinones associated with encephalopathy, coma, convulsions, sympathomimetic toxidrome, hallucinogenic toxidrome, excited delirium syndrome, and serotonin syndrome. Neurotoxicity linked to excessive monoamine release.

**Sympathomimetic toxidrome (Debruyne et al. 2014 [Ref 29]; Kele\u010devi\u0107 et al. 2024 [Ref 13]; B\u00e4ckberg et al. 2015 [Ref 15]):**  
Expected acute toxidrome based on 3-MMC intoxication data: tachycardia (48%), agitation (42%), reduced level of consciousness (32%), mydriasis (24%), hallucinations (20%), diaphoresis (12%), seizures (8%), hyperthermia (6%). These figures derive from the Swedish STRIDA project (3-MMC cases) and are presented as class-level analogy for 2-MMC.

**Alcohol interaction (Ciudad-Roberts et al. 2016 [Ref 30]):**  
Ethanol combined with mephedrone (4-MMC) in adolescent mice produced approximately 2-fold greater neurotoxicity than mephedrone alone (measured by DAT, TH, SERT, and TPH reductions in frontal cortex and hippocampus), plus impaired hippocampal neurogenesis and memory. Approximately 95% of cathinone users report combining with alcohol — a high-prevalence, high-risk combination.

**Immunoassay interference (Willeman et al. 2025 [Ref 3]):**  
2-MMC causes **false-positive amphetamine immunoassay results at ≥50 μg/mL** (EMIT Atellica CH, Siemens). This has clinical significance: cathinone intoxication may be underreported or misidentified in emergency settings relying on immunoassay screening. Confirmatory mass spectrometry is required for definitive identification.

**Fatal cases:** No published case reports specifically attributing death to 2-MMC alone. Fatalities from 3-MMC (closest isomer) typically involve polydrug combinations (e.g., 3-MMC + 5-APB + alcohol, Adamowicz et al. 2014 [Ref 4 context]; 3-MMC + GHB, Drevin et al. 2021 [Ref 15 context]).

---

## Harm Reduction

Based on class-level evidence; no 2-MMC-specific harm reduction publications exist.

**Key harm reduction principles from literature:**

1. **Testing**: Standard immunoassay strips (amphetamine, MDMA) will NOT reliably detect 2-MMC. Mass spectrometry or specialized cathinone immunoassays required (Willeman et al. 2025 [Ref 3]). Reagent testing (Marquis, Mecke, Simon's) can provide presumptive identification but cannot distinguish isomers.

2. **Avoid polydrug combinations**: Most severe cathinone toxicity cases involve combinations. Alcohol co-use is extremely common (~95% of users, Ciudad-Roberts 2016 [Ref 30]) and substantially increases neurotoxicity. GHB combination documented in 3-MMC chemsex fatality (Drevin 2021 [Ref cited in text]).

3. **Avoid MAOIs**: By mechanism (monoamine releasing agent), combination with MAOIs poses severe serotonin syndrome risk. No 2-MMC-specific data, but class contraindication is absolute based on mechanism.

4. **Temperature regulation**: Hyperthermia is a recognized cathinone class risk, particularly at high doses, during physical exertion, or in hot environments (dance venues). Hydration and cooling are critical.

5. **Redosing compulsion**: 2/3-MMC's shorter duration specifically leads to more intense redosing urge compared to 4-MMC (van Amsterdam 2025 [Ref 16]). Setting limits before use and having a trusted person present is recommended by harm reduction organizations.

6. **Injection route**: High-risk setting (chemsex/slamsex context documented; EUDA 2026 [Ref 31]). Shares all IV stimulant risks (vascular damage, infection, overdose risk).

7. **Emergency response**: No specific antidote; management is supportive (Debruyne 2014 [Ref 29]). Emergency presentations should be treated as stimulant/sympathomimetic toxidrome: benzodiazepines for agitation/seizures; cooling for hyperthermia; cardiac monitoring.

---

## Tolerance & Dependence

No 2-MMC-specific tolerance or dependence data published.

**Class-level evidence (van Amsterdam et al. 2025 [Ref 16]; Debruyne et al. 2014 [Ref 29]):**

- 2/3-MMC have **greater craving and more frequent redosing compared to 4-MMC**, suggesting a potentially higher dependence liability despite similar pharmacological class.
- Treatment-seeking for problematic 3-MMC use in the Netherlands rose from 33 individuals (2021) to 330 (2023) following legal prohibition (market substitute effect combined with escalating use).
- Most treatment-seeking cases involve polydrug users.
- DAT-predominant cathinones (high dopaminergic drive) are associated with high addiction potential per Simmler et al. 2013 [Ref 22] and Liechti 2015 [Ref 23] pharmacological classification.

**Withdrawal:** No published withdrawal characterization for 2-MMC. Class withdrawal (from stimulant cathinone cessation) would be expected to resemble amphetamine withdrawal: fatigue, dysphoria, hypersomnia, increased appetite, craving — based on class mechanism.

**Cross-tolerance:** Expected with other monoamine releasing agents (amphetamines, MDMA, 3-MMC, 4-MMC) based on shared DAT/NET/SERT mechanism. No 2-MMC-specific data.

---

## Interactions

No published drug interaction data specifically for 2-MMC. All interactions below are mechanism-based class inferences.

**⚠️ FLAG: All interaction severity ratings below are inferred, not substance-verified. Require editorial assignment of severity levels.**

| Interaction | Mechanism | Evidence Level |
|---|---|---|
| MAOIs (phenelzine, tranylcypromine, selegiline) | Catastrophic monoamine accumulation + serotonin syndrome | Class mechanism (monoamine releaser); no 2-MMC data |
| SSRIs / SNRIs | Additive serotonergic activity; serotonin syndrome risk | Class mechanism; reduced via SERT competition |
| Other stimulants (amphetamines, cocaine, MDMA) | Cardiovascular overload, hyperthermia, additive monoamine surge | Class mechanism; documented for cathinone class |
| Alcohol | Increases cathinone neurotoxicity ~2-fold; CNS combination impairs judgment | Mephedrone+EtOH mice data [Ref 30]; 95% real-world co-use prevalence |
| GHB/GBL | CNS depression + stimulant masking; documented in chemsex fatalities | 3-MMC+GHB case (Drevin 2021 [Ref cited in text]) |
| Lithium | Lowers seizure threshold; documented with MDMA and stimulants | Class inference only |
| Cannabis | Additive anxiety and cardiovascular effects | Class inference |

---

## Legal Status

| Jurisdiction | Status | Legislation | Notes |
|---|---|---|---|
| EU (all member states) | Controlled | Delegated Directive (EU) 2025/2062 | Entered force 12 Jan 2026; member state implementation deadline 12 July 2026 [Ref 31] |
| United Kingdom | Controlled | Psychoactive Substances Act 2016 | Blanket ban on psychoactive substances; 2-MMC not specifically scheduled under Misuse of Drugs Act 1971 |
| Australia | Prohibited | Schedule 9 (Prohibited Substance) | Illegal to manufacture, possess, sell |
| United States | Uncertain | Federal Analogue Act (21 USC §813) | Not specifically scheduled by DEA; potentially covered as analogue of Schedule I cathinone; prosecution-dependent |
| China | Controlled | National Drug Control regulations | Controlled October 2015; drove shift in supply to India [Ref 18] |
| Netherlands | Controlled (pending EU implementation) | Opium Act amendments | 3-MMC banned Oct 2021; 2-MMC use surged; full control expected under EU implementation |

---

## Clinical Trials

No clinical trials involving 2-MMC were found on ClinicalTrials.gov. Search returned zero results for "2-methylmethcathinone" and "cathinone" combined.

---

## Community Feedback Analysis

No community feedback was submitted for this substance (Part A2 of brief is empty).

---

## Gaps & Flags

### Critical data absent from published literature

1. **⚠️ SAFETY-CRITICAL — No substance-specific binding affinity data:** No Ki or EC50 values at DAT, NET, or SERT for 2-MMC have been published. The pharmacological class designation "monoamine releasing agent" is inferred from structural analogy to 3-MMC and 4-MMC, and from the comparative statement in van Amsterdam et al. 2025. Generation agent must state this absence explicitly and attribute any mechanism claims to structural analogy.

2. **⚠️ SAFETY-CRITICAL — No published LD50 or toxicity thresholds:** No lethality data in any species. No therapeutic index. Dangerous dose thresholds are unknown and cannot be proposed.

3. **No human pharmacokinetic data:** Bioavailability, Tmax, half-life, and plasma protein binding are unpublished. Duration estimates derive from user reports and indirect comparison to 4-MMC.

4. **No controlled human dosing studies:** All dose data are user-report (KnowDrugs platform). The dose ranges (oral: 20–135 mg; intranasal: 5–80 mg) are plausible for a mephedrone-class cathinone but unverified against any controlled study. **These must be proposed with user_report_only confidence tier and editorial flag.**

5. **No 2-MMC-specific receptor binding at TAAR1 or other secondary targets:** Mephedrone and other cathinones act at TAAR1 (trace amine-associated receptor 1) in some studies, but this has not been assessed for 2-MMC. The Simmler 2013 study found cathinones are NOT TAAR1 ligands (unlike amphetamines), but this was not tested for 2-MMC specifically.

6. **SMILES unverified by API:** The SMILES string CC1=CC=CC=C1C(=O)C(C)NC was obtained from web search results, not from a direct API return from PubChem (PubChem API did not return SMILES in the tool output). It is consistent with the IUPAC name and the positional isomer description, but should be confirmed against PubChem CID 56603536 structure data before use.

7. **Enantiomeric activity unknown:** 2-MMC's chiral center creates two enantiomers. Which enantiomer predominates in commercial preparations and which is pharmacologically active has not been published. The enantioselective method of Kobidze et al. 2025 detected both enantiomers in oral fluid samples but did not report pharmacological preference data.

8. **No 2-MMC-specific case reports:** No published emergency presentations, fatalities, or case series specifically attributing adverse events to 2-MMC mono-ingestion. All safety inferences derive from 3-MMC and 4-MMC cases and class-level reviews.

9. **Legal status US — unresolved:** 2-MMC does not appear to be specifically scheduled by the DEA. Applicability of the Federal Analogue Act depends on prosecutorial context (substantially similar structure/pharmacology to a Schedule I substance + intended for human consumption). This should be reviewed by a legal expert and flagged in the article.

10. **pKa value not extracted:** Nowak et al. 2018 [Ref 5] measured 2-MMC's pKa but the specific numerical value was not available in the abstract. Full paper access would be needed to report this value.

11. **Seed data verified:** The brief's characterization as "Phenethylamine, Substituted phenethylamine, Amphetamine, Cathinone, Substituted cathinone" for chemical class and "Monoamine releasing agent" for pharmacological class and "Stimulant" for psychoactive class are all consistent with the evidence found. No seed data contradictions detected, but the pharmacological class assignment requires the flag noted in gap #1.